FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU von Niederhausern, B
   Schandelmaier, S
   Bonde, MM
   Brunner, N
   Hemkens, LG
   Rutquist, M
   Bhatnagar, N
   Guyatt, GH
   Pauli-Magnus, C
   Briel, M
AF von Niederhausern, Belinda
   Schandelmaier, Stefan
   Bonde, Marie Mi
   Brunner, Nicole
   Hemkens, Lars G.
   Rutquist, Marielle
   Bhatnagar, Neera
   Guyatt, Gordon H.
   Pauli-Magnus, Christiane
   Briel, Matthias
TI Towards the development of a comprehensive framework: Qualitative
   systematic survey of definitions of clinical research quality
SO PLOS ONE
LA English
DT Article
ID REDUCING WASTE; INCREASING VALUE; BIOMEDICAL-RESEARCH;
   RANDOMIZED-TRIALS; HEALTH-CARE; ELABORATION; EXPLANATION; REVIEWS;
   STATEMENT; ISSUES
AB Objective
   To systematically survey existing definitions, concepts, and criteria of clinical research quality, both developed by stakeholder groups as well as in the medical literature. This study serves as a first step in the development of a comprehensive framework for the quality of clinical research.
   Study design and setting
   We systematically and in duplicate searched definitions, concepts and criteria of clinical research quality on websites of stakeholders in clinical research until no further insights emerged and in MEDLINE up to February 2015. Stakeholders included governmental bodies, regulatory agencies, the pharmaceutical industry, academic and commercial contract research organizations, initiatives, research ethics committees, patient organizations and funding agencies from 13 countries. Data synthesis involved descriptive and qualitative analyses following the Framework Method on definitions, concepts, and criteria of clinical research quality. Descriptive codes were applied and grouped into clusters to identify common and stakeholder-specific quality themes.
   Results
   Stakeholder concepts on how to assure quality throughout study conduct or articles on quality assessment tools were common, generally with no a priori definition of the term quality itself. We identified a total of 20 explicit definitions of clinical research quality including varying quality dimensions and focusing on different stages in the clinical research process. Encountered quality dimensions include ethical conduct, patient safety/rights/priorities, internal validity, precision of results, generalizability or external validity, scientific and societal relevance, transparency and accessibility of information, research infrastructure and sustainability. None of the definitions appeared to be comprehensive either in terms of quality dimensions, research stages, or stakeholder perspectives.
   Conclusion
   Clinical research quality is often discussed but rarely defined. A framework defining clinical research quality across stakeholders' individual perspectives is desirable to facilitate discussion, assessment, and improvement of quality at all stages of clinical research.
C1 [von Niederhausern, Belinda; Bonde, Marie Mi; Brunner, Nicole; Rutquist, Marielle; Pauli-Magnus, Christiane] Univ Hosp Basel, Dept Clin Res, Clin Trial Unit, Basel, Switzerland.
   [Schandelmaier, Stefan; Hemkens, Lars G.; Briel, Matthias] Univ Hosp Basel, Basel Inst Clin Epidemiol & Biostat, Dept Clin Res, Basel, Switzerland.
   [Schandelmaier, Stefan; Bhatnagar, Neera; Guyatt, Gordon H.; Briel, Matthias] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.
RP von Niederhausern, B (reprint author), Univ Hosp Basel, Dept Clin Res, Clin Trial Unit, Basel, Switzerland.
EM belinda.vonniederhausern@usb.ch
OI Schandelmaier, Stefan/0000-0002-8429-0337
CR Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012
   Amtenbrink F., 2015, EVALUATING DUTCH LEG, P447
   Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015
   Bhatt Arun, 2011, Perspect Clin Res, V2, P124, DOI 10.4103/2229-3485.86880
   Cabral AP, 2014, PROCD SOC BEHV, V116, P1528, DOI 10.1016/j.sbspro.2014.01.429
   Chalmers I, 2014, LANCET, V383, P156, DOI 10.1016/S0140-6736(13)62229-1
   Chan AW, 2014, LANCET, V383, P257, DOI 10.1016/S0140-6736(13)62296-5
   Chan AW, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e7586
   Coulter A, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-S2-S2
   Dawn AG, 2003, AM J MED QUAL, V18, P265, DOI 10.1177/106286060301800607
   DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743
   Donabedian A, 1980, DEFINITION QUALITY A
   Dugas M, 2017, BMC MED INFORM DECIS, V17, DOI 10.1186/s12911-016-0399-8
   Franck Linda S, 2004, Int J Health Care Qual Assur Inc Leadersh Health Serv, V17, P239, DOI 10.1108/09526860410549344
   Frank L, 2015, QUAL LIFE RES, V24, P1033, DOI 10.1007/s11136-014-0893-3
   Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117
   Glasziou P, 2014, LANCET, V383, P267, DOI 10.1016/S0140-6736(13)62228-X
   Grimes DA, 2005, LANCET, V366, P172, DOI 10.1016/S0140-6736(05)66875-4
   Guyatt GH, 2008, BMJ-BRIT MED J, V336, P995, DOI 10.1136/bmj.39490.551019.BE
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Ioannidis JPA, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002049
   Ioannidis JPA, 2014, LANCET, V383, P166, DOI 10.1016/S0140-6736(13)62227-8
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jenkinson C, 2002, INT J QUAL HEALTH C, V14, P353, DOI 10.1093/intqhc/14.5.353
   Juni P, 2001, BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42
   Kasenda B, 2014, JAMA-J AM MED ASSOC, V311, P1045, DOI 10.1001/jama.2014.1361
   Kellow A, 2012, EUR POLIT SCI, V11, P567, DOI 10.1057/eps.2011.70
   Krestin GP, 2008, RADIOLOGY, V249, P418, DOI 10.1148/radiol.2491080832
   Liberati A, 2009, ANN INTERN MED, V151, pW65, DOI 10.7326/0003-4819-151-4-200908180-00136
   Macleod MR, 2014, LANCET, V383, P101, DOI 10.1016/S0140-6736(13)62329-6
   McMahon AD, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000131
   Moher D, 1996, INT J TECHNOL ASSESS, V12, P195, DOI 10.1017/S0266462300009570
   Njie VPS, 2001, J PROF NURS, V17, P233, DOI 10.1053/jpnu.2001.26308
   Patrick WJ, 1996, RES HIGH EDUC, V37, P23, DOI 10.1007/BF01680040
   Rajan A, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-274
   Salman RA, 2014, LANCET, V383, P176, DOI 10.1016/S0140-6736(13)62297-7
   Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919
   Stewart PM, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1732
   Switula D, 2006, SCI ENG ETHICS, V12, P147, DOI 10.1007/s11948-006-0015-x
   Urden Linda D, 2002, Lippincotts Case Manag, V7, P194, DOI 10.1097/00129234-200209000-00006
   Vandenbroucke JP, 2014, INT J SURG, V12, P1500, DOI 10.1016/j.ijsu.2014.07.014
   Verhagen AP, 2001, J CLIN EPIDEMIOL, V54, P651, DOI 10.1016/S0895-4356(00)00360-7
   Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009
   WOOLF SH, 1992, ARCH INTERN MED, V152, P946, DOI 10.1001/archinte.152.5.946
NR 44
TC 2
Z9 2
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 17
PY 2017
VL 12
IS 7
AR e0180635
DI 10.1371/journal.pone.0180635
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GS8PU
UT WOS:000443975500013
PM 28715491
OA Other Gold, Green Published
DA 2019-05-24
ER

PT J
AU Azar, M
   Riehm, KE
   McKay, D
   Thombs, BD
AF Azar, Marleine
   Riehm, Kira E.
   McKay, Dean
   Thombs, Brett D.
TI Transparency of Outcome Reporting and Trial Registration of Randomized
   Controlled Trials Published in the Journal of Consulting and Clinical
   Psychology
SO PLOS ONE
LA English
DT Article
ID CONSORT STATEMENT; PUBLICATION BIAS; ELABORATION; EXPLANATION; EDITORS;
   STANDARDS; PROTOCOLS; POLICIES; THERAPY
AB Background
   Confidence that randomized controlled trial (RCT) results accurately reflect intervention effectiveness depends on proper trial conduct and the accuracy and completeness of published trial reports. The Journal of Consulting and Clinical Psychology (JCCP) is the primary trials journal amongst American Psychological Association (APA) journals. The objectives of this study were to review RCTs recently published in JCCP to evaluate (1) adequacy of primary outcome analysis definitions; (2) registration status; and, (3) among registered trials, adequacy of outcome registrations. Additionally, we compared results from JCCP to findings from a recent study of top psychosomatic and behavioral medicine journals.
   Methods
   Eligible RCTs were published in JCCP in 2013-2014. For each RCT, two investigators independently extracted data on (1) adequacy of outcome analysis definitions in the published report, (2) whether the RCT was registered prior to enrolling patients, and (3) adequacy of outcome registration.
   Results
   Of 70 RCTs reviewed, 12 (17.1%) adequately defined primary or secondary outcome analyses, whereas 58 (82.3%) had multiple primary outcome analyses without statistical adjustment or undefined outcome analyses. There were 39 (55.7%) registered trials. Only two trials registered prior to patient enrollment with a single primary outcome variable and time point of assessment. However, in one of the two trials, registered and published outcomes were discrepant. No studies were adequately registered as per Standard Protocol Items: Recommendation for Interventional Trials guidelines. Compared to psychosomatic and behavioral medicine journals, the proportion of published trials with adequate outcome analysis declarations was significantly lower in JCCP (17.1% versus 32.9%; p = 0.029). The proportion of registered trials in JCCP (55.7%) was comparable to behavioral medicine journals (52.6%; p = 0.709).
   Conclusions
   The quality of published outcome analysis definitions and trial registrations in JCCP is suboptimal. Greater attention to proper trial registration and outcome analysis definition in published reports is needed.
C1 [Azar, Marleine; Riehm, Kira E.; Thombs, Brett D.] McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada.
   [Azar, Marleine; Riehm, Kira E.; Thombs, Brett D.] McGill Univ, Dept Psychol, Montreal, PQ, Canada.
   [McKay, Dean] Fordham Univ, Dept Psychol, Bronx, NY 10458 USA.
   [Thombs, Brett D.] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada.
   [Thombs, Brett D.] McGill Univ, Dept Psychiat, Montreal, PQ, Canada.
   [Thombs, Brett D.] McGill Univ, Dept Med, Montreal, PQ, Canada.
   [Thombs, Brett D.] McGill Univ, Dept Educ & Counselling Psychol, Montreal, PQ, Canada.
   [Thombs, Brett D.] McGill Univ, Sch Nursing, Montreal, PQ, Canada.
RP Thombs, BD (reprint author), McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada.
EM brett.thombs@mcgill.ca
FU CIHR Frederick Banting and Charles Best Canadian Graduate Scholarships -
   Master's Award; Arthritis Society
FX Although this study was not supported by any sources of funding,
   individual authors are supported by funding agencies. Marleine Azar is
   supported by a CIHR Frederick Banting and Charles Best Canadian Graduate
   Scholarships - Master's Award (http://cihr-irsc.gc.ca). Dr. Brett Thombs
   receives support from an Investigator Award from the Arthritis Society
   (http://www.arthritis.ca/page.aspx?pid=1068). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012
   APA, 2015, J CONSULTING CLIN PS
   APA, 2015, J ABNORMAL PSYCHOL
   Arthur A, 2003, EDITORIAL MODIFICATI
   Boutron I, 2008, ANN INTERN MED, V148, P295, DOI 10.7326/0003-4819-148-4-200802190-00008
   Brice A, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6170
   CHALMERS I, 1985, BRIT MED J, V290, P1002, DOI 10.1136/bmj.290.6473.1002
   Chan AW, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e7586
   Chan AW, 2004, JAMA-J AM MED ASSOC, V291, P2457, DOI 10.1001/jama.291.20.2457
   Cook JM, 2007, SCI REV MENTAL HLTH, V5
   Cooper H, 2008, AM PSYCHOL, V63, P839, DOI 10.1037/0003-066X.63.9.839
   Creed F, 2011, J PSYCHOSOM RES, V70, P203, DOI 10.1016/j.jpsychores.2011.01.011
   Dal-Re R, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1323
   De Angelis C, 2004, NEW ENGL J MED, V351, P1250, DOI 10.1056/NEJMe048225
   Enkin M.W., 2007, BIAS RANDOMIZED CONT
   Friedmen LM, 2010, FUNDAMENTALS OF CLINICAL TRIALS, FOURTH EDITION, P1
   Kaplan RM, 2002, ANN BEHAV MED, V24, P167, DOI 10.1207/S15324796ABM2403_01
   KOREN G, 1991, JAMA-J AM MED ASSOC, V266, P1824, DOI 10.1001/jama.266.13.1824
   Luborsky L, 1999, CLIN PSYCHOL-SCI PR, V6, P95, DOI 10.1093/clipsy/6.1.95
   Mathieu S, 2009, JAMA-J AM MED ASSOC, V302, P977, DOI 10.1001/jama.2009.1242
   Milette K, 2011, J PSYCHOSOM RES, V70, P205, DOI 10.1016/j.jpsychores.2010.09.015
   Moher D, 2012, INT J SURG, V10, P28, DOI 10.1016/j.ijsu.2011.10.001
   Murray GD, 2000, STAT METHODS MED RES, V9, P17, DOI 10.1191/096228000670253839
   Nezu AM, 2011, J CONSULT CLIN PSYCH, V79, P1, DOI 10.1037/a0022353
   Olthuis JV, 2014, J CONSULT CLIN PSYCH, V82, P1005, DOI 10.1037/a0037027
   Page MJ, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000035.pub2
   Page MJ, 2013, J CLIN EPIDEMIOL, V66, P524, DOI 10.1016/j.jclinepi.2012.10.010
   Pocock SJ, 1997, CONTROL CLIN TRIALS, V18, P530, DOI 10.1016/S0197-2456(97)00008-1
   Riehm KE, 2015, J PSYCHOSOMATIC RES
   Rogers K, 2014, J CONSULT CLIN PSYCH, V82, P361, DOI 10.1037/a0035744
   Saquib N, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4313
   Schulz KF, 2010, ANN INTERN MED, V152, P726, DOI 10.7326/0003-4819-152-11-201006010-00232
   Schulz KF, 2005, LANCET, V365, P1591, DOI 10.1016/S0140-6736(05)66461-6
   Schulz KF, 2005, LANCET, V365, P1348, DOI 10.1016/S0140-6736(05)61034-3
   Sheps DS, 2003, PSYCHOSOM MED, V65, P499, DOI 10.1097/01.PSY.0000082398.68127.9B
   Smyth RMD, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.c7153
   Song FJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110418
   Sterne JAC, 2011, COCHRANE HDB SYSTEMA
   Thorn BE, 2007, J CLIN PSYCHOL, V63, P607, DOI 10.1002/jclp.20384
   Turner L, 2012, SYST REV, V1, DOI 10.1186/2046-4053-1-60
   Wager E, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5248
NR 41
TC 11
Z9 11
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 18
PY 2015
VL 10
IS 11
AR e0142894
DI 10.1371/journal.pone.0142894
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CW7CD
UT WOS:000365154600066
PM 26581079
OA Green Published, Other Gold
DA 2019-05-24
ER

PT J
AU Kagesten, A
   Tuncalp, O
   Ali, M
   Chandra-Mouli, V
   Tran, N
   Gulmezoglu, AM
AF Kagesten, Anna
   Tuncalp, Oezge
   Ali, Moazzam
   Chandra-Mouli, Venkatraman
   Tran, Nhan
   Guelmezoglu, A. Metin
TI A Systematic Review of Reporting Tools Applicable to Sexual and
   Reproductive Health Programmes: Step 1 in Developing Programme Reporting
   Standards
SO PLOS ONE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIALS; COMPLEX INTERVENTIONS; CLINICAL-TRIALS;
   PUBLICATION GUIDELINES; QUALITATIVE RESEARCH; DIAGNOSTIC-ACCURACY;
   CONSORT STATEMENT; STARE-HI; IMPLEMENTATION; CHECKLIST
AB Background
   Complete and accurate reporting of programme preparation, implementation and evaluation processes in the field of sexual and reproductive health (SRH) is essential to understand the impact of SRH programmes, as well as to guide their replication and scale-up.
   Objectives
   To provide an overview of existing reporting tools and identify core items used in programme reporting with a focus on programme preparation, implementation and evaluation processes.
   Methods
   A systematic review was completed for the period 2000-2014. Reporting guidelines, checklists and tools, irrespective of study design, applicable for reporting on programmes targeting SRH outcomes, were included. Two independent reviewers screened the title and abstract of all records. Full texts were assessed in duplicate, followed by data extraction on the focus, content area, year of publication, validation and description of reporting items. Data was synthesized using an iterative thematic approach, where items related to programme preparation, implementation and evaluation in each tool were extracted and aggregated into a consolidated list.
   Results Out of the 3,656 records screened for title and abstracts, full texts were retrieved for 182 articles, out of which 108 were excluded. Seventy-four full text articles corresponding to 45 reporting tools were retained for synthesis. The majority of tools were developed for reporting on intervention research (n = 15), randomized controlled trials (n = 8) and systematic reviews (n = 7). We identified a total of 50 reporting items, across three main domains and corresponding sub-domains: programme preparation (objective/focus, design, piloting); programme implementation (content, timing/duration/location, providers/staff, participants, delivery, implementation outcomes), and programme evaluation (process evaluation, implementation barriers/facilitators, outcome/impact evaluation).
   Conclusions
   Over the past decade a wide range of tools have been developed to improve the reporting of health research. Development of Programme Reporting Standards (PRS) for SRH can fill a significant gap in existing reporting tools. This systematic review is the first step in the development of such standards. In the next steps, we will draft a preliminary version of the PRS based on the aggregate list of identified items, and finalize the tool using a consensus process among experts and user-testing.
C1 [Kagesten, Anna] Johns Hopkins Sch Publ Hlth, Dept Populat Family & Reprod Hlth, Baltimore, MD 21205 USA.
   [Tuncalp, Oezge; Ali, Moazzam; Chandra-Mouli, Venkatraman; Guelmezoglu, A. Metin] WHO, WHO Dept Reprod Hlth & Res, UNDP UNFPA UNICEF WHO World Bank Special Programm, CH-1211 Geneva, Switzerland.
   [Tran, Nhan] WHO, Alliance Hlth Policy & Syst Res, Implementat Res Platform, CH-1211 Geneva, Switzerland.
RP Kagesten, A (reprint author), Johns Hopkins Sch Publ Hlth, Dept Populat Family & Reprod Hlth, Baltimore, MD 21205 USA.
EM akaagesten@jhu.edu
RI Tuncalp, Ozge/Y-2724-2018
OI Tuncalp, Ozge/0000-0002-5370-682X
FU Alliance for Health Policy and Systems Research (AHPSR)
FX The current study was funded by the Alliance for Health Policy and
   Systems Research (AHPSR), hosted by the WHO
   (http://www.who.int/alliance-hpsr/about/en/). Nhan Tran at AHPSR
   contributed with materials and preparation of the manuscript.
CR Abraham C, 2014, JAIDS-J ACQ IMM DEF, V66, pS293, DOI 10.1097/QAI.0000000000000231
   Albrecht L, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-52
   Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012
   Altman DG, 2012, STAT MED, V31, P2985, DOI 10.1002/sim.5402
   Armstrong R, 2008, J PUBLIC HEALTH-UK, V30, P103, DOI 10.1093/pubmed/fdm082
   Baker TB, 2010, PATIENT EDUC COUNS, V81, pS77, DOI 10.1016/j.pec.2010.07.040
   Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637
   Bennett C, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001069
   Bird VJ, 2014, BRIT J PSYCHIAT, V204, P316, DOI 10.1192/bjp.bp.113.128314
   Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010
   Boutron I, 2005, J CLIN EPIDEMIOL, V58, P1233, DOI 10.1016/j.jclinepi.2005.05.004
   Boutron I, 2008, ANN INTERN MED, V148, pW60, DOI 10.7326/0003-4819-148-4-200802190-00008-w1
   Burford BJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075122
   Chalmers I, 2014, LANCET, V383, P156, DOI 10.1016/S0140-6736(13)62229-1
   Chalmers I, 2009, LANCET, V374, P86, DOI 10.1016/S0140-6736(09)60329-9
   Conn VS, 2011, NURS OUTLOOK, V59, P318, DOI 10.1016/j.outlook.2011.06.003
   Davidoff F, 2008, QUAL SAF HEALTH CARE, V17, P3, DOI 10.1136/qshc.2008.029066
   Davidson KW, 2003, ANN BEHAV MED, V26, P161, DOI 10.1207/S15324796ABM2603_01
   Des Jarlais DC, 2004, AM J PUBLIC HEALTH, V94, P361, DOI 10.2105/AJPH.94.3.361
   Durlak JA, 2008, AM J COMMUN PSYCHOL, V41, P327, DOI 10.1007/s10464-008-9165-0
   Egger M, 2001, JAMA-J AM MED ASSOC, V285, P1996, DOI 10.1001/jama.285.15.1996
   Eysenbach G, 2011, J MED INTERNET RES, V13, P25
   Fernald D, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.120004
   Flores SA, 2004, AIDS EDUC PREV, V16, P341, DOI 10.1521/aeap.16.4.341.40396
   Flottorp SA, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-35
   Glasziou P, 2014, LANCET, V383, P267, DOI 10.1016/S0140-6736(13)62228-X
   Harrington NG, 2012, HEALTH EDUC RES, V27, P331, DOI 10.1093/her/cyr108
   Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]
   Husereau D, 2013, VALUE HEALTH, V16, pE1, DOI 10.1016/j.jval.2013.02.010
   Husereau D, 2013, VALUE HEALTH, V16, P231, DOI 10.1016/j.jval.2013.02.002
   Kogesten A, 2014, AM J PUBLIC HEALTH, V104, pE23, DOI 10.2105/AJPH.2014.302246
   Kavanagh J, 2008, REFLECTIONS DEV USIN
   Last J., 2000, DICT EPIDEMIOLOGY
   Liberati A, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000100
   Little J, 2009, J CLIN EPIDEMIOL, V62, P597, DOI 10.1016/j.jclinepi.2008.12.004
   MacPherson Hugh, 2002, Acupunct Med, V20, P22
   MacPherson H, 2010, J ALTERN COMPLEM MED, V16, P929, DOI 10.1089/acm.2010.0558
   MacPherson H, 2010, ACUPUNCT MED, V28, P83, DOI 10.1136/aim.2009.001370
   Matsumoto M, 2012, RURAL REMOTE HEALTH, V12
   Mayo-Wilson E, 2007, AM J PUBLIC HEALTH, V97, P630, DOI 10.2105/AJPH.2006.094169
   Mayo-Wilson E, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-242
   Michie S, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-40
   Mohler R, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-125
   Mohler R, 2012, INT J NURS STUD, V49, P40, DOI 10.1016/j.ijnurstu.2011.08.003
   Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987
   Moher D, 2011, J CLIN EPIDEMIOL, V64, P718, DOI 10.1016/j.jclinepi.2010.09.013
   Moher D, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000217
   Moher D, 2010, BMJ-BRIT MED J, V340, DOI [10.1136/bmj.c869, 10.1016/j.jclinepi.2010.03.004]
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   Montgomery P, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-99
   Montgomery P, 2013, J CLIN EPIDEMIOL, V66, P874, DOI 10.1016/j.jclinepi.2013.03.006
   Niazkhani Z, 2011, STUD HEALTH TECHNOL, V169, P877, DOI 10.3233/978-1-60750-806-9-877
   O'Neill J, 2014, J CLIN EPIDEMIOL, V67, P56, DOI 10.1016/j.jclinepi.2013.08.005
   Ogrinc G, 2008, QUAL SAF HEALTH CARE, V17, P13, DOI 10.1136/qshc.2008.029058
   Peters DH, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6753
   Peters DH, 2013, INPLEMENTATION RESEARCH IN HEALTH: A PRACTICAL GUIDE, P1
   Phillips A, 2014, TURNING THE PAGE: THE EVOLUTION OF THE BOOK, P1
   Phillips AC, 2014, BMC MED EDUC, V14, DOI 10.1186/1472-6920-14-159
   Phillips AC, 2013, BMC MED EDUC, V13, DOI 10.1186/1472-6920-13-9
   Pinnock H, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-015-0235-z
   Proudfoot Judith, 2011, Cognitive Behaviour Therapy, V40, P82, DOI 10.1080/16506073.2011.573807
   Ramsey S, 2005, VALUE HEALTH, V8, P521, DOI 10.1111/j.1524-4733.2005.00045.x
   Rigby M, 2009, STUD HEALTH TECHNOL, V150, P66, DOI 10.3233/978-1-60750-044-5-66
   Roen K, 2006, SOC SCI MED, V63, P1060, DOI 10.1016/j.socscimed.2006.02.013
   Schulz KF, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-32
   Simel DL, 2008, J GEN INTERN MED, V23, P768, DOI 10.1007/s11606-008-0583-3
   Smidt Nynke, 2006, BMC Med Res Methodol, V6, P12, DOI 10.1186/1471-2288-6-12
   Staniszewska S, 2011, INT J TECHNOL ASSESS, V27, P391, DOI 10.1017/S0266462311000481
   Stein KF, 2010, J AM PSYCHIAT NURSES, V16, P337
   Talmon J, 2009, INT J MED INFORM, V78, P1, DOI 10.1016/j.ijmedinf.2008.09.002
   The SURE Collaboration, 2011, SURE GUID PREP US EV
   Thomas CW, 2006, AIDS EDUC PREV, V18, P74, DOI 10.1521/aeap.2006.18.supp.74
   Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042
   Tong A, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-181
   Tooth L, 2005, AM J EPIDEMIOL, V161, P280, DOI 10.1093/aje/kwi042
   Vandenbroucke JP, 2007, PLOS MED, V4, P1628, DOI 10.1371/journal.pmed.0040297
   von Elm E, 2007, PLOS MED, V4, P1623, DOI 10.1371/journal.pmed.0040296
   Welch V, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001333
   Welch V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031360
   Welch VA, 2013, SYST REV, V2, DOI 10.1186/2046-4053-2-43
   Wells GA, 2013, RES SYNTH METHODS, V4, P63, DOI 10.1002/jrsm.1077
   Wells M, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-95
   WHO Sexual and Reproductive Health, WHO SEX REPR HLTH
   WHO (World Health Organization), 2011, BEG END MIND PLANN P
   Zwarenstein M, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2390
NR 85
TC 4
Z9 4
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 29
PY 2015
VL 10
IS 9
AR e0138647
DI 10.1371/journal.pone.0138647
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CS6EV
UT WOS:000362171400018
PM 26418859
OA DOAJ Gold, Green Published
DA 2019-05-24
ER

PT J
AU Hafkamp-de Groen, E
   van der Valk, RJP
   Mohangoo, AD
   van der Wouden, JC
   Duijts, L
   Jaddoe, VW
   Hofman, A
   de Koning, HJ
   de Jongste, JC
   Raat, H
AF Hafkamp-de Groen, Esther
   van der Valk, Ralf J. P.
   Mohangoo, Ashna D.
   van der Wouden, Johannes C.
   Duijts, Liesbeth
   Jaddoe, Vincent W.
   Hofman, Albert
   de Koning, Harry J.
   de Jongste, Johan C.
   Raat, Hein
TI Evaluation of Systematic Assessment of Asthma-Like Symptoms and Tobacco
   Smoke Exposure in Early Childhood by Well-Child Professionals: A
   Randomised Trial
SO PLOS ONE
LA English
DT Article
ID PRESCHOOL-CHILDREN; BASE-LINE; PRIMARY PREVENTION; MULTIPLE IMPUTATION;
   CONSORT STATEMENT; SUBGROUP ANALYSIS; FOLLOW-UP; HEALTH; QUESTIONNAIRE;
   INTERVENTION
AB Objectives: This study aimed to evaluate the effectiveness of systematic assessment of asthma-like symptoms and environmental tobacco smoke (ETS) exposure during regular preventive well-child visits between age 1 and 4 years by well-child professionals.
   Methods: Sixteen well-child centres in Rotterdam, the Netherlands, were randomised into 8 centres where the brief assessment form regarding asthma-like symptoms and ETS exposure was used and 8 centres that applied usual care. 3596 and 4179 children (born between April 2002 and January 2006) and their parents visited the intervention and control centres, respectively. At child's age 6 years, physician-diagnosed asthma ever, wheezing, fractional exhaled nitric oxide (FeNO), airway resistance (Rint), health-related quality of life (HRQOL) and ETS exposure at home ever were measured. Linear mixed models were applied.
   Results: No differences in asthma, wheezing, FeNO, Rint or HRQOL measurements between intervention and control group were found using multilevel regression in an intention-to-treat analysis (p > 0.05). Children of whom the parents were interviewed by using the brief assessment form at the intervention well-child centres had a decreased risk on ETS exposure at home ever, compared to children who visited the control well-child centres, in an explorative per-protocol analysis (aOR = 0.71, 95% CI: 0.59-0.87).
   Conclusions: Systematic assessment and counselling of asthma-like symptoms and ETS exposure in early childhood by well-child care professionals using a brief assessment form was not effective in reducing the prevalence of physician-diagnosed asthma ever and wheezing, and did not improve FeNO, Rint or HRQOL at age 6 years. Our results hold some promise for interviewing parents and using information leaflets at well-child centres to reduce ETS exposure at home in preschool children.
C1 [Hafkamp-de Groen, Esther; van der Valk, Ralf J. P.; Jaddoe, Vincent W.] Erasmus MC, Generat R Study Grp, Rotterdam, Netherlands.
   [Hafkamp-de Groen, Esther; de Koning, Harry J.; Raat, Hein] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands.
   [van der Valk, Ralf J. P.; Duijts, Liesbeth; de Jongste, Johan C.] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Div Resp Med, Dept Paediat, Rotterdam, Netherlands.
   [van der Valk, Ralf J. P.; Duijts, Liesbeth; Jaddoe, Vincent W.; Hofman, Albert] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Mohangoo, Ashna D.] TNO, Netherlands Org Appl Sci Res, Dept Child Hlth, Leiden, Netherlands.
   [van der Wouden, Johannes C.] Vrije Univ Amsterdam, Med Ctr, EMGO, Dept Gen Practice & Elderly Care Med, Amsterdam, Netherlands.
   [Duijts, Liesbeth] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Div Neonatol, Dept Paediat, Rotterdam, Netherlands.
   [Jaddoe, Vincent W.] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Dept Paediat, Rotterdam, Netherlands.
RP Hafkamp-de Groen, E (reprint author), Erasmus MC, Generat R Study Grp, Rotterdam, Netherlands.
EM e.hafkamp@erasmusmc.nl
RI van der Wouden, Johannes C/O-5109-2019
OI van der Wouden, Johannes/0000-0001-6639-6050
FU Netherlands Organisation for Health Research and Development (ZonMw)
   [22000128]; European Respiratory Society/Marie Curie Joint Research
   Fellowship [MC 1226-2009, PCOFUND-GA-2008-229571]; Netherlands
   Organization for Health Research and Development (ZonMw - VIDI)
FX This study was funded by the Netherlands Organisation for Health
   Research and Development (ZonMw: project no. 22000128). L. Duijts
   received funding by means of a European Respiratory Society/Marie Curie
   Joint Research Fellowship (MC 1226-2009) under grant agreement RESPIRE,
   PCOFUND-GA-2008-229571. V. W. Jaddoe received additional grants from the
   Netherlands Organization for Health Research and Development (ZonMw -
   VIDI). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012
   [American Thoracic Society European Respiratory Society], 2005, AM J RESP CRIT CARE, V171, P912, DOI DOI 10.1164/RCCM.200406-710ST
   Arshad SH, 2003, THORAX, V58, P489, DOI 10.1136/thorax.58.6.489
   Assmann SF, 2000, LANCET, V355, P1064, DOI 10.1016/S0140-6736(00)02039-0
   Becker A, 2004, J ALLERGY CLIN IMMUN, V113, P650, DOI 10.1016/j.jaci.2004.01.754
   Beydon N, 2003, AM J RESP CRIT CARE, V168, P640, DOI 10.1164/rccm.200303-449OC
   Brunekreef B, 2000, EPIDEMIOLOGY, V11, P350, DOI 10.1097/00001648-200005000-00023
   Burgmeijer RJF, 1997, OP WEG NAAR VOLWASSE
   Campbell MK, 2004, BMJ-BRIT MED J, V328, P702, DOI 10.1136/bmj.328.7441.702
   Cane RS, 2000, ARCH DIS CHILD, V82, P327, DOI 10.1136/adc.82.4.327
   Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029
   CPB Netherlands Bureau for Economic Policy Analysis, 2005, 133 CPB, V133
   Dijkstra NS, 2001, PROGRAMMERINGSTUDIE
   Duijts L, 2012, CHEST, V141, P876, DOI 10.1378/chest.11-0112
   Emmons KM, 2001, AM J PREV MED, V20, P68, DOI 10.1016/S0749-3797(00)00254-3
   Greenland S, 1999, EPIDEMIOLOGY, V10, P37, DOI 10.1097/00001648-199901000-00008
   Hafkamp-de Groen E, 2012, BMC PULM MED, V12, DOI 10.1186/1471-2466-12-65
   Hafkamp-de Groen E, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-555
   HealthActChQ, 2008, CHILD HLTH QUEST SCO
   Howden-Chapman P, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1411
   Jaddoe VWV, 2012, EUR J EPIDEMIOL, V27, P739, DOI 10.1007/s10654-012-9735-1
   Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609
   Lai CKW, 2009, THORAX, V64, P476, DOI 10.1136/thx.2008.106609
   Landgraf JM, 1999, CHILD HLTH QUESTIONN
   Lanphear BP, 2001, PEDIATRICS, V107, P505, DOI 10.1542/peds.107.3.505
   Margolis PA, 1997, PEDIATR PULM, V23, P417, DOI 10.1002/(SICI)1099-0496(199706)23:6<417::AID-PPUL4>3.0.CO;2-F
   Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x
   Merkus PJFM, 2010, EUR RESPIR J, V36, P157, DOI 10.1183/09031936.00125009
   Ministry of Health Welfare and Sport, 2003, BAS JEUGDG HEIDSZ 0
   PATRICK DL, 1994, AM J PUBLIC HEALTH, V84, P1086, DOI 10.2105/AJPH.84.7.1086
   Pilotto LS, 2004, INT J EPIDEMIOL, V33, P208, DOI 10.1093/ije/dyh018
   Pocock SJ, 2002, STAT MED, V21, P2917, DOI 10.1002/sim.1296
   Postma J, 2009, J ASTHMA, V46, P564, DOI 10.1080/02770900902912638
   Priest N, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001746.pub2
   Raat H, 2005, J EPIDEMIOL COMMUN H, V59, P75, DOI 10.1136/jech.2003.012614
   Schonberger HJAM, 2005, EUR RESPIR J, V25, P660, DOI 10.1183/09031936.05.00067704
   Spratt M, 2010, AM J EPIDEMIOL, V172, P478, DOI 10.1093/aje/kwq137
   *STAT NETH, 2004, DUTCH STAND CLASS ED
   Sterne JAC, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2393
   Sun X, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c117
   SWERTZ O, 2004, MIGRANTS NETHERLANDS
   Taylor DR, 2006, THORAX, V61, P817, DOI 10.1136/thx.2005.056093
   Twisk J, 2004, J CLIN EPIDEMIOL, V57, P223, DOI 10.1016/j.jclinepi.2003.07.009
   Twisk JWR, 2006, APPL MULTILEVEL ANAL
   van der Valk RJP, 2013, ALLERGY, V68, P788, DOI 10.1111/all.12146
   Vickers AJ, 2001, BMJ-BRIT MED J, V323, P1123, DOI 10.1136/bmj.323.7321.1123
   Wang XB, 1997, INT J EPIDEMIOL, V26, P978, DOI 10.1093/ije/26.5.978
   Wilson SR, 2011, CHEST, V139, P581, DOI 10.1378/chest.10-0772
   Wilson SR, 2001, CHEST, V120, P1709, DOI 10.1378/chest.120.5.1709
   Wit E., 2004, STAT MICROARRAYS
NR 50
TC 1
Z9 1
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 13
PY 2014
VL 9
IS 3
AR e90982
DI 10.1371/journal.pone.0090982
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AC9JS
UT WOS:000332851300046
PM 24626147
OA DOAJ Gold, Green Published
DA 2019-05-24
ER

PT J
AU Fritz, H
   Seely, D
   Flower, G
   Skidmore, B
   Fernandes, R
   Vadeboncoeur, S
   Kennedy, D
   Cooley, K
   Wong, R
   Sagar, S
   Sabri, E
   Fergusson, D
AF Fritz, Heidi
   Seely, Dugald
   Flower, Gillian
   Skidmore, Becky
   Fernandes, Rochelle
   Vadeboncoeur, Sarah
   Kennedy, Deborah
   Cooley, Kieran
   Wong, Raimond
   Sagar, Stephen
   Sabri, Elham
   Fergusson, Dean
TI Soy, Red Clover, and Isoflavones and Breast Cancer: A Systematic Review
SO PLOS ONE
LA English
DT Review
ID DIETARY PHYTOESTROGEN INTAKE; ESTROGEN-RECEPTOR-ALPHA;
   TRIFOLIUM-PRATENSE L.; NIPPLE ASPIRATE FLUID; POSTMENOPAUSAL WOMEN;
   MAMMOGRAPHIC DENSITY; IN-VITRO; PREMENOPAUSAL WOMEN; MENOPAUSAL
   SYMPTOMS; URINARY-EXCRETION
AB Background: Soy and red clover isoflavones are controversial due to purported estrogenic activity and possible effects on breast cancer. We conducted a systematic review of soy and red clover for efficacy in improving menopausal symptoms in women with breast cancer, and for potential impact on risk of breast cancer incidence or recurrence.
   Methods: We searched MEDLINE, Embase, the Cochrane Library, and AMED from inception to March 2013 for human interventional or observational data pertaining to the safety and efficacy of soy and red clover isoflavones in patients with or at risk of breast cancer.
   Results: Of 4179 records, we included a total of 131 articles: 40 RCTs, 11 uncontrolled trials, and 80 observational studies. Five RCTs reported on the efficacy of soy for hot flashes, showing no significant reductions in hot flashes compared to placebo. There is lack of evidence showing harm from use of soy with respect to risk of breast cancer or recurrence, based on long term observational data. Soy intake consistent with that of a traditional Japanese diet (2-3 servings daily, containing 25-50mg isoflavones) may be protective against breast cancer and recurrence. Human trials show that soy does not increase circulating estradiol or affect estrogen-responsive target tissues. Prospective data of soy use in women taking tamoxifen does not indicate increased risk of recurrence. Evidence on red clover is limited, however existing studies suggest that it may not possess breast cancer-promoting effects.
   Conclusion: Soy consumption may be associated with reduced risk of breast cancer incidence, recurrence, and mortality. Soy does not have estrogenic effects in humans. Soy intake consistent with a traditional Japanese diet appears safe for breast cancer survivors. While there is no clear evidence of harm, better evidence confirming safety is required before use of high dose (>= 100mg) isoflavones can be recommended for breast cancer patients.
C1 [Fritz, Heidi; Seely, Dugald; Flower, Gillian; Fernandes, Rochelle; Vadeboncoeur, Sarah; Kennedy, Deborah; Cooley, Kieran] Canadian Coll Naturopath Med, Dept Res & Clin Epidemiol, Toronto, ON, Canada.
   [Seely, Dugald; Skidmore, Becky; Sabri, Elham; Fergusson, Dean] Ottawa Hosp, Res Inst, Ottawa, ON, Canada.
   [Seely, Dugald] Ottawa Integrat Canc Ctr, Ottawa, ON, Canada.
   [Fernandes, Rochelle] Univ Toronto, LMP, Toronto, ON, Canada.
   [Kennedy, Deborah; Cooley, Kieran] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada.
   [Wong, Raimond; Sagar, Stephen] McMaster Univ, Juravinski Canc Ctr, Hamilton, ON, Canada.
   [Wong, Raimond; Sagar, Stephen] McMaster Univ, Dept Med, Hamilton, ON, Canada.
RP Seely, D (reprint author), Canadian Coll Naturopath Med, Dept Res & Clin Epidemiol, Toronto, ON, Canada.
EM dseely@ccnm.edu
RI Cooley, Kieran/L-3080-2019
OI Cooley, Kieran/0000-0001-7960-6504; Fergusson, Dean/0000-0002-3389-2485;
   Skidmore, Becky/0000-0001-8293-9238
FU Canadian Institutes of Health Research; Sickkids Foundation
FX This project was funded by a Knowledge Synthesis grant from the Canadian
   Institutes of Health Research. DAK was supported by a career grant from
   the Sickkids Foundation. No other sources of funding were accessed. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012
   Amado NG, 2011, LIFE SCI, V89, P545, DOI 10.1016/j.lfs.2011.05.003
   An GH, 2011, BIOPHARM DRUG DISPOS, V32, P446, DOI 10.1002/bdd.772
   Anderson LN, 2011, AM J EPIDEMIOL, V173, pS312
   Anderson LN, 2013, INT J CANCER, V132, P1683, DOI 10.1002/ijc.27788
   Andres S, 2011, TOXICOL LETT, V205, pS264, DOI 10.1016/j.toxlet.2011.05.898
   Andres S, 2011, CRIT REV TOXICOL, V41, P463, DOI 10.3109/10408444.2010.541900
   Archer DF, 2011, CLIMACTERIC, V14, P515, DOI 10.3109/13697137.2011.608596
   Asensi M, 2011, CRIT REV CL LAB SCI, V48, P197, DOI 10.3109/10408363.2011.631268
   Atkinson C, 2004, BREAST CANCER RES, V6, pR170, DOI 10.1186/bcr773
   Bandera EV, 2011, BMC WOMENS HEALTH, V11, DOI 10.1186/1472-6874-11-40
   Barnes S, 2011, FOOD FUNCT, V2, P235, DOI 10.1039/c1fo10025d
   Bhanot A., 2011, INT J PHYTOMED, V3, P9, DOI DOI 10.1016/J.FOODCHEM.2010.11.023
   Body JJ, 2011, ACTA CLIN BELG, V66, P443, DOI 10.2143/ACB.66.6.2062612
   BONI V, 2011, J CLIN ONCOLOGY S1, V29, P1
   Booth NL, 2006, J AGR FOOD CHEM, V54, P1277, DOI 10.1021/jf052927u
   Booth NL, 2006, MENOPAUSE, V13, P251, DOI 10.1097/01.gme.0000198297.40269.f7
   Booth NL, 2006, J ALTERN COMPLEM MED, V12, P133, DOI 10.1089/acm.2006.12.133
   BOUCHER BA, 2011, AM J EPIDEMIOL S11, V173, pS87
   Boucher BA, 2013, INT J CANCER, V132, P1439, DOI 10.1002/ijc.27769
   Boumendjel A, 2011, CURR MED CHEM, V18, P3387, DOI 10.2174/092986711796504736
   Boyapati SM, 2005, BREAST CANCER RES TR, V92, P11, DOI 10.1007/s10549-004-6019-9
   Brasky TM, 2010, CANCER EPIDEM BIOMAR, V19, P1696, DOI 10.1158/1055-9965.EPI-10-0318
   Brown BD, 2002, NUTR CANCER, V43, P22, DOI 10.1207/S15327914NC431_2
   Caan BJ, 2011, CANCER EPIDEM BIOMAR, V20, P854, DOI 10.1158/1055-9965.EPI-10-1041
   CASSIDY A, 1994, AM J CLIN NUTR, V60, P333
   Chen J, 2011, HORM METAB RES, V43, P681, DOI 10.1055/s-0031-1286306
   Chen JLY, 2011, MEDCHEMCOMM, V2, P229, DOI 10.1039/c0md00241k
   Chen J, 2011, CANCER LETT, V308, P144, DOI 10.1016/j.canlet.2011.04.022
   Cho YA, 2010, EUR J CLIN NUTR, V64, P924, DOI 10.1038/ejcn.2010.95
   Choi EJ, 2011, INT J ONCOL, V39, P747, DOI 10.3892/ijo.2011.1067
   Chu Zhao-hui, 2011, Zhong Xi Yi Jie He Xue Bao, V9, P533
   CIOTTA L, 2011, CLIM C 13 WORLD C ME, V14, P192
   Clemente A, 2011, CURR PROTEIN PEPT SC, V12, P358, DOI 10.2174/138920311796391133
   Cohen LA, 2007, IN VIVO, V21, P507
   Cotterchio M, 2008, CANCER CAUSE CONTROL, V19, P259, DOI 10.1007/s10552-007-9089-2
   Dai Q, 2003, CANCER EPIDEM BIOMAR, V12, P497
   Dai Q, 2002, CANCER EPIDEM BIOMAR, V11, P815
   Dai Q, 2001, BRIT J CANCER, V85, P372, DOI 10.1054/bjoc.2001.1873
   Dave B, 2005, CARCINOGENESIS, V26, P1793, DOI 10.1093/carcin/bgi131
   DESANTIS C, 2011, BREAST CANC STAT
   DiSilvestro RA, 2005, BREAST CANCER RES TR, V89, P251, DOI 10.1007/s10549-004-2227-6
   Do MH, 2007, NUTR CANCER, V57, P20, DOI 10.1080/01635580701268063
   Dooley WC, 2006, J CLIN ONCOL, V24, p36S
   Dorjgochoo T, 2011, BREAST CANCER RES TR, V130, P879, DOI 10.1007/s10549-010-1096-4
   DOS SSI, 2004, CANCER CAUSE CONTROL, V15, P805, DOI DOI 10.1023/B:CAC0.0000043431.85706.D8.PUBMED:15456994
   Doyle C, 2006, CA-CANCER J CLIN, V56, P323, DOI 10.3322/canjclin.56.6.323
   Duncan AM, 1999, J CLIN ENDOCR METAB, V84, P192, DOI 10.1210/jc.84.1.192
   Duncan AM, 2000, CANCER EPIDEM BIOMAR, V9, P581
   Fink BN, 2007, CANCER EPIDEM BIOMAR, V16, P2285, DOI 10.1158/1055-9965.EPI-07-0245
   Frankenfeld CL, 2004, CANCER EPIDEM BIOMAR, V13, P1156
   Fritz H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021107
   Gagnier JJ, 2006, J CLIN EPIDEMIOL, V59, P1134, DOI 10.1016/j.jclinepi.2005.12.020
   Goodman MT, 2009, CANCER PREV RES, V2, P887, DOI 10.1158/1940-6207.CAPR-09-0039
   Grace PB, 2004, CANCER EPIDEM BIOMAR, V13, P698
   Guha N, 2009, BREAST CANCER RES TR, V118, P395, DOI 10.1007/s10549-009-0321-5
   Hall MC, 2007, STEROIDS, V72, P64, DOI 10.1016/j.steroids.2006.10.010
   Harris DM, 2005, EXP BIOL MED, V230, P558, DOI 10.1177/153537020523000807
   Harris PF, 2002, J PAIN SYMPTOM MANAG, V23, P501, DOI 10.1016/S0885-3924(02)00395-0
   Hedelin M, 2008, J NUTR, V138, P938
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   HIROSE K, 1995, JPN J CANCER RES, V86, P146, DOI 10.1111/j.1349-7006.1995.tb03032.x
   Hirose K, 2003, INT J CANCER, V107, P276, DOI 10.1002/ijc.11373
   Ho SY, 2006, PREV MED, V43, P20, DOI 10.1016/j.ypmed.2006.03.007
   Horn-Ross PL, 2001, AM J EPIDEMIOL, V154, P434, DOI 10.1093/aje/154.5.434
   Horn-Ross PL, 2002, CANCER CAUSE CONTROL, V13, P407, DOI 10.1023/A:1015786030864
   Hwang CS, 2006, J STEROID BIOCHEM, V101, P246, DOI 10.1016/j.jsbmb.2006.06.020
   *I OHR, NEWC OTT SCAL NOS
   Imhof M, 2008, TOXICOL IN VITRO, V22, P1452, DOI 10.1016/j.tiv.2008.04.018
   Ingram D, 1997, LANCET, V350, P990, DOI 10.1016/S0140-6736(97)01339-1
   Iwasaki M, 2008, J CLIN ONCOL, V26, P1677, DOI 10.1200/JCO.2007.13.9964
   Iwasaki M, 2010, NUTR CANCER, V62, P466, DOI 10.1080/01635580903441279
   Iwasaki M, 2009, CANCER SCI, V100, P927, DOI 10.1111/j.1349-7006.2009.01118.x
   Iwasaki M, 2009, BREAST CANCER RES TR, V116, P401, DOI 10.1007/s10549-008-0168-1
   Jou HJ, 2008, INT J GYNECOL OBSTET, V102, P44, DOI 10.1016/j.ijgo.2008.01.028
   Ju YH, 2006, CARCINOGENESIS, V27, P1292, DOI 10.1093/carcin/bgi370
   Kang HB, 2012, ASIAN PAC J CANCER P, V13, P995, DOI 10.7314/APJCP.2012.13.3.995
   Kang XM, 2010, CAN MED ASSOC J, V182, P1857, DOI 10.1503/cmaj.091298
   Kataoka M, 2008, MATURITAS, V59, P350, DOI 10.1016/j.maturitas.2008.03.005
   Keinan-Boker L, 2004, AM J CLIN NUTR, V79, P282
   Key TJ, 1999, BRIT J CANCER, V81, P1248, DOI 10.1038/sj.bjc.6690837
   Khan SA, 2012, CANCER PREV RES, V5, P309, DOI 10.1158/1940-6207.CAPR-11-0251
   Kim MK, 2008, NUTR CANCER, V60, P568, DOI 10.1080/01635580801966203
   Koehler KF, 2005, ENDOCR REV, V26, P465, DOI 10.1210/er.2004-0027
   Korde LA, 2009, CANCER EPIDEM BIOMAR, V18, P1050, DOI 10.1158/1055-9965.EPI-08-0405
   Kostelac D, 2003, J AGR FOOD CHEM, V51, P7632, DOI 10.1021/jf034427b
   Kumar NB, 2002, CANCER-AM CANCER SOC, V94, P1166, DOI 10.1002/cncr.10320
   Lammersfeld CA, 2009, NUTR J, V8, DOI 10.1186/1475-2891-8-2
   Lampe JW, 2007, CANCER EPIDEM BIOMAR, V16, P2579, DOI 10.1158/1055-9965.EPI-07-0368
   LEE HP, 1992, CANCER CAUSE CONTROL, V3, P313, DOI 10.1007/BF00146884
   Lee MM, 2005, CANCER CAUSE CONTROL, V16, P929, DOI 10.1007/s10552-005-4932-9
   Lee SA, 2009, AM J CLIN NUTR, V89, P1920, DOI 10.3945/ajcn.2008.27361
   Li M, 2005, CANCER RES, V65, P8200, DOI 10.1158/0008-5472.CAN-05-1302
   Li N, 2010, BREAST CANCER RES TR, V121, P177, DOI 10.1007/s10549-009-0532-9
   Lu LJW, 2000, CANCER RES, V60, P4112
   Lu LJW, 1996, CANCER EPIDEM BIOMAR, V5, P63
   Lu LJW, 2001, J CLIN ENDOCR METAB, V86, P3045, DOI 10.1210/jc.86.7.3045
   Lu LJW, 2000, CANCER RES, V60, P1299
   Ma HY, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-109
   MacGregor CA, 2005, EUR J CANCER, V41, P708, DOI 10.1016/j.ejca.2005.01.005
   Mai ZM, 2007, MOL CARCINOGEN, V46, P534, DOI 10.1002/mc.20300
   Mai ZM, 2007, CARCINOGENESIS, V28, P1217, DOI 10.1093/carcin/bgm004
   Marini H, 2008, J CLIN ENDOCR METAB, V93, P4787, DOI 10.1210/jc.2008-1087
   Martini MC, 1999, NUTR CANCER, V34, P133, DOI 10.1207/S15327914NC3402_2
   Maskarinec G, 2004, J NUTR, V134, P3089
   Maskarinec G, 2006, CANCER EPIDEM BIOMAR, V15, P732, DOI 10.1158/1055-9965.EPI-05-0798
   Maskarinec G, 2005, NUTR CANCER, V52, P22, DOI 10.1207/s15327914nc5201_3
   Maskarinec G, 2004, CANCER EPIDEM BIOMAR, V13, P1736
   Maskarinec G, 2002, IARC Sci Publ, V156, P375
   Maskarinec G, 2012, EUR J CLIN NUTR, V66, P1044, DOI 10.1038/ejcn.2012.71
   Maskarinec G, 2002, CANCER EPIDEM BIOMAR, V11, P195
   Maskarinec G, 2008, EUR J CANCER PREV, V17, P67, DOI 10.1097/CEJ.0b013e3281108101
   Maskarinec G, 2011, CANCER EPIDEM BIOMAR, V20, P1815, DOI 10.1158/1055-9965.EPI-11-0363
   Maskarinec G, 2011, J NUTR, V141, P626, DOI 10.3945/jn.110.133769
   Maskarinec G, 2009, NUTR CANCER, V61, P708, DOI 10.1080/01635580902913047
   Maskarinec G, 2009, J NUTR, V139, P981, DOI 10.3945/jn.108.102913
   Maskarinec GF, 2003, EUR J CANCER PREV, V12, P165, DOI 10.1097/01.cej.0000062792.86004.69
   McLaughlin JM, 2011, CANCER PREV RES, V4, P702, DOI 10.1158/1940-6207.CAPR-10-0329
   McMichael-Phillips DF, 1998, AM J CLIN NUTR, V68, p1431S, DOI 10.1093/ajcn/68.6.1431S
   Messina M, 2006, NUTR CANCER, V55, P1, DOI 10.1207/s15327914nc5501_1
   Messina M, 2009, AM J CLIN NUTR, V89, pS1673, DOI 10.3945/ajcn.2009.26736V
   Morimoto Y, 2012, NUTR CANCER, V64, P307, DOI 10.1080/01635581.2012.648819
   Morimoto Y, 2011, FOOD FUNCT, V2, P665, DOI 10.1039/c1fo10144g
   Morito K, 2001, BIOL PHARM BULL, V24, P351, DOI 10.1248/bpb.24.351
   Murkies A, 2000, MENOPAUSE, V7, P289, DOI 10.1097/00042192-200007050-00003
   Nagata C, 1998, JNCI-J NATL CANCER I, V90, P1830, DOI 10.1093/jnci/90.23.1830
   Nagel G, 2005, EUR J MED RES, V10, P389
   Nechuta SJ, 2012, AM J CLIN NUTR, V96, P123, DOI 10.3945/ajcn.112.035972
   Nettleton JA, 2005, J NUTR, V135, P603
   Nikander E, 2004, J CLIN ENDOCR METAB, V89, P1207, DOI 10.1210/jc.2003-031166
   Nikander E, 2003, OBSTET GYNECOL, V101, P1213, DOI 10.1016/S0029-7844(03)00232-1
   Nishio K, 2007, CANCER CAUSE CONTROL, V18, P801, DOI 10.1007/s10552-007-9023-7
   Palacios S, 2010, CLIMACTERIC, V13, P368, DOI 10.3109/13697131003660585
   Park K, 2009, EXP MOL MED, V41, P371, DOI 10.3858/emm.2009.41.6.042
   Peterson J, 2003, BRIT J CANCER, V89, P1255, DOI 10.1038/sj.bjc.6601271
   Petrakis NL, 1996, CANCER EPIDEM BIOMAR, V5, P785
   Piller R, 2006, EUR J CANCER PREV, V15, P225, DOI 10.1097/01.cej.0000197449.56862.75
   Pop EA, 2008, MENOPAUSE, V15, P684, DOI 10.1097/gme.0b013e318167b8f2
   Powles Trevor J, 2008, Menopause Int, V14, P6, DOI 10.1258/mi.2007.007033
   Qin WY, 2009, NUTR CANCER, V61, P238, DOI 10.1080/01635580802404196
   Quella SK, 2000, J CLIN ONCOL, V18, P1068, DOI 10.1200/JCO.2000.18.5.1068
   Rajah TT, 2009, PHARMACOLOGY, V84, P68, DOI 10.1159/000226123
   Ravindranath MH, 2004, ADV EXP MED BIOL, V546, P121
   Sampson M, 2009, J CLIN EPIDEMIOL, V62, P944, DOI 10.1016/j.jclinepi.2008.10.012
   Sanderson M, 2004, NUTR CANCER, V50, P8, DOI 10.1207/s15327914nc5001_2
   Saviranta NMM, 2010, ENVIRON POLLUT, V158, P440, DOI 10.1016/j.envpol.2009.08.029
   Saviranta NMM, 2010, J SCI FOOD AGR, V90, P418, DOI 10.1002/jsfa.3831
   Setchell KDR, 2005, AM J CLIN NUTR, V81, P1072
   Shannon J, 2005, CANCER EPIDEM BIOMAR, V14, P81
   Shu XO, 2009, JAMA-J AM MED ASSOC, V302, P2437, DOI 10.1001/jama.2009.1783
   Shu XO, 2001, CANCER EPIDEM BIOMAR, V10, P483
   Steinberg FM, 2011, AM J CLIN NUTR, V93, P356, DOI 10.3945/ajcn.110.008359
   Suzuki T, 2008, INT J CANCER, V123, P1674, DOI 10.1002/ijc.23644
   Thanos J, 2006, CANCER CAUSE CONTROL, V17, P1253, DOI 10.1007/s10552-006-0062-2
   Touillaud MS, 2006, CANCER EPIDEM BIOMAR, V15, P2574, DOI 10.1158/1055-9965.EPI-06-0543
   Touillaud MS, 2005, NUTR CANCER, V51, P162, DOI 10.1207/s15327914nc5102_6
   Travis RC, 2008, INT J CANCER, V122, P705, DOI 10.1002/ijc.23141
   van Duursen MBM, 2011, TOXICOLOGY, V289, P67, DOI 10.1016/j.tox.2011.07.005
   Van Patten CL, 2002, J CLIN ONCOL, V20, P1449, DOI 10.1200/JCO.20.6.1449
   Velders M, 2010, J STEROID BIOCHEM, V120, P53, DOI 10.1016/j.jsbmb.2010.03.059
   Verheus M, 2007, J CLIN ONCOL, V25, P648, DOI 10.1200/JCO.2006.06.0244
   Wang L, 2009, AM J CLIN NUTR, V89, P905, DOI 10.3945/ajcn.2008.26913
   Wang Q, 2011, DNA CELL BIOL, V30, P585, DOI 10.1089/dna.2010.1195
   Wang Qiong, 2010, Chin J Cancer, V29, P683
   Ward H, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1995
   Ward HA, 2010, ARCH BIOCHEM BIOPHYS, V501, P170, DOI 10.1016/j.abb.2010.05.018
   Witte JS, 1997, BREAST CANCER RES TR, V42, P243, DOI 10.1023/A:1005710211184
   Wong JMW, 2012, AM J CLIN NUTR, V95, P564, DOI 10.3945/ajcn.111.017418
   Woo HD, 2012, NUTR CANCER, V64, P198, DOI 10.1080/01635581.2012.635261
   Wu AH, 2008, BRIT J CANCER, V98, P9, DOI 10.1038/sj.bjc.6604145
   Wu AH, 2005, AM J CLIN NUTR, V81, P1133
   Wu AH, 1996, CANCER EPIDEM BIOMAR, V5, P901
   Wu AH, 2002, CARCINOGENESIS, V23, P1491, DOI 10.1093/carcin/23.9.1491
   Wu AH, 2000, BRIT J CANCER, V82, P1879, DOI 10.1054/bjoc.1999.1218
   Wu AH, 2009, AM J CLIN NUTR, V89, P1145, DOI 10.3945/ajcn.2008.26915
   Xu X, 2000, CANCER EPIDEM BIOMAR, V9, P781
   Yamamoto S, 2003, J NATL CANCER I, V95, P906, DOI 10.1093/jnci/95.12.906
   YUAN JM, 1995, BRIT J CANCER, V71, P1353, DOI 10.1038/bjc.1995.263
   Zaineddin AK, 2012, NUTR CANCER, V64, P652, DOI 10.1080/01635581.2012.683227
   Zgorka G, 2011, J AOAC INT, V94, P22
   Zhang CX, 2010, CANCER SCI, V101, P501, DOI 10.1111/j.1349-7006.2009.01376.x
   Zhang M, 2010, NUTR CANCER, V62, P765, DOI 10.1080/01635581003605979
   Zhang M, 2009, BREAST CANCER RES TR, V118, P553, DOI 10.1007/s10549-009-0354-9
   Zhang YF, 2012, ASIAN PAC J CANCER P, V13, P479, DOI 10.7314/APJCP.2012.13.1.479
   Zheng W, 1999, CANCER EPIDEM BIOMAR, V8, P35
   Zhu YY, 2011, ASIAN PAC J CANCER P, V12, P2837
   Zittermann A, 2004, EUR J NUTR, V43, P100, DOI 10.1007/s00394-004-0447-5
NR 187
TC 59
Z9 59
U1 1
U2 63
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 28
PY 2013
VL 8
IS 11
AR UNSP e81968
DI 10.1371/journal.pone.0081968
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 261IJ
UT WOS:000327657900065
PM 24312387
OA Green Published, Other Gold
DA 2019-05-24
ER

PT J
AU Knuppel, H
   Metz, C
   Meerpohl, JJ
   Strech, D
AF Knueppel, Hannes
   Metz, Courtney
   Meerpohl, Joerg J.
   Strech, Daniel
TI How Psychiatry Journals Support the Unbiased Translation of Clinical
   Research. A Cross-Sectional Study of Editorial Policies
SO PLOS ONE
LA English
DT Article
ID CONSORT STATEMENT; RANDOMIZED-TRIALS; EMPIRICAL-EVIDENCE; MEDICAL
   JOURNALS; PUBLICATION; QUALITY; INSTRUCTIONS; BIAS; REGISTRATION;
   EXPLANATION
AB Introduction: Reporting guidelines (e. g. CONSORT) have been developed as tools to improve quality and reduce bias in reporting research findings. Trial registration has been recommended for countering selective publication. The International Committee of Medical Journal Editors (ICMJE) encourages the implementation of reporting guidelines and trial registration as uniform requirements (URM). For the last two decades, however, biased reporting and insufficient registration of clinical trials has been identified in several literature reviews and other investigations. No study has so far investigated the extent to which author instructions in psychiatry journals encourage following reporting guidelines and trial registration.
   Method: Psychiatry Journals were identified from the 2011 Journal Citation Report. Information given in the author instructions and during the submission procedure of all journals was assessed on whether major reporting guidelines, trial registration and the ICMJE's URM in general were mentioned and adherence recommended.
   Results: We included 123 psychiatry journals (English and German language) in our analysis. A minority recommend or require 1) following the URM (21%), 2) adherence to reporting guidelines such as CONSORT, PRISMA, STROBE (23%, 7%, 4%), or 3) registration of clinical trials (34%). The subsample of the top-10 psychiatry journals (ranked by impact factor) provided much better but still improvable rates. For example, 70% of the top-10 psychiatry journals do not ask for the specific trial registration number.
   Discussion: Under the assumption that better reported and better registered clinical research that does not lack substantial information will improve the understanding, credibility, and unbiased translation of clinical research findings, several stakeholders including readers (physicians, patients), authors, reviewers, and editors might benefit from improved author instructions in psychiatry journals. A first step of improvement would consist in requiring adherence to the broadly accepted reporting guidelines and to trial registration.
C1 [Knueppel, Hannes; Metz, Courtney; Strech, Daniel] Hannover Med Sch, Inst Hist & Eth Med, CELLS, Hannover, Germany.
   [Metz, Courtney] Leibniz Univ Hannover, Dept Philosophy, CELLS, Hannover, Germany.
   [Meerpohl, Joerg J.] Univ Med Ctr Freiburg, German Cochrane Ctr, Inst Med Biometry & Med Informat, Freiburg, Germany.
RP Strech, D (reprint author), Hannover Med Sch, Inst Hist & Eth Med, CELLS, Hannover, Germany.
EM strech.daniel@mh-hannover.de
RI Meerpohl, Joerg J/J-4224-2013
OI Meerpohl, Joerg J/0000-0002-1333-5403; Kahrass,
   Hannes/0000-0003-0694-0354; Strech, Daniel/0000-0002-9153-079X
CR Altman DG, 2005, BRIT MED J, V330, P1056, DOI 10.1136/bmj.330.7499.1056
   Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012
   Brody H, 2012, NEW ENGL J MED, V366, P1949, DOI 10.1056/NEJMp1203365
   Chan AW, 2004, JAMA-J AM MED ASSOC, V291, P2457, DOI 10.1001/jama.291.20.2457
   Cipriani A, 2007, J CLIN PSYCHOPHARM, V27, P352, DOI 10.1097/jcp.0b013e3180a9081f
   Dans AL, 1998, JAMA-J AM MED ASSOC, V279, P545, DOI 10.1001/jama.279.7.545
   De Angelis C, 2004, ANN INTERN MED, V141, P477, DOI 10.7326/0003-4819-141-6-200409210-00109
   Demicheli V, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000003.pub2
   Dickersin K, 2003, JAMA-J AM MED ASSOC, V290, P516, DOI 10.1001/jama.290.4.516
   Dickersin K, 1997, AIDS EDUC PREV, V9, P15
   Han C, 2009, CONTEMP CLIN TRIALS, V30, P116, DOI 10.1016/j.cct.2008.11.004
   Hopewell S, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-20
   ICMJE, 2008, UN REQ UNPUB
   Juni P, 2001, BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42
   Kunath F, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000430
   Kunath F, 2012, UROL INT, V88, P54, DOI 10.1159/000332742
   LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605
   Levin LA, 2007, ARCH INTERN MED, V167, P1576, DOI 10.1001/archinte.167.15.1576
   McHenry L, 2006, J MED ETHICS, V32, P405, DOI 10.1136/jme.2005.013185
   Meerpohl JJ, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-27
   Meerpohl JJ, 2010, ARCH PEDIAT ADOL MED, V164, P268, DOI 10.1001/archpediatrics.2009.287
   Melander H, 2003, BMJ-BRIT MED J, V326, P1171, DOI 10.1136/bmj.326.7400.1171
   Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1992, DOI 10.1001/jama.285.15.1992
   Moher D, 2011, J CLIN EPIDEMIOL, V64, P718, DOI 10.1016/j.jclinepi.2010.09.013
   Moher D, 2010, BMJ-BRIT MED J, V340, DOI [10.1136/bmj.c869, 10.1016/j.jclinepi.2010.03.004]
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Rising K, 2008, PLOS MED, V5, P1561, DOI 10.1371/journal.pmed.0050217
   SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408
   Soltmann B, 2012, NERVENARZT, V83, P604, DOI 10.1007/s00115-011-3418-0
   Strech D, 2012, J CLIN EPIDEMIOL, V65, P276, DOI 10.1016/j.jclinepi.2011.07.002
   Strech D, 2011, J CLIN PSYCHIAT, V72, P1214, DOI 10.4088/JCP.10r06166yel
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Thornley B, 1998, BRIT MED J, V317, P1181, DOI 10.1136/bmj.317.7167.1181
   Turner EH, 2008, NEW ENGL J MED, V358, P252, DOI 10.1056/NEJMsa065779
   von Elm E, 2007, PREV MED, V45, P247, DOI [10.1016/j.ypmed.2007.08.012, 10.7326/0003-4819-147-8-200710160-00010]
   Whittington CJ, 2004, LANCET, V363, P1341, DOI 10.1016/S0140-6736(04)16043-1
NR 36
TC 16
Z9 16
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 16
PY 2013
VL 8
IS 10
AR e75995
DI 10.1371/journal.pone.0075995
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 239JR
UT WOS:000326019400029
PM 24146806
OA Other Gold, Green Published
DA 2019-05-24
ER

PT J
AU Tamminga, SJ
   Verbeek, JHAM
   Bos, MMEM
   Fons, G
   Kitzen, JJEM
   Plaisier, PW
   Frings-Dresen, MHW
   de Boer, AGEM
AF Tamminga, Sietske J.
   Verbeek, Jos H. A. M.
   Bos, Monique M. E. M.
   Fons, Guus
   Kitzen, Jos J. E. M.
   Plaisier, Peter W.
   Frings-Dresen, Monique H. W.
   de Boer, Angela G. E. M.
TI Effectiveness of a Hospital-Based Work Support Intervention for Female
   Cancer Patients - A Multi-Centre Randomised Controlled Trial
SO PLOS ONE
LA English
DT Article
ID QUALITY-OF-LIFE; RETURN-TO-WORK; BREAST-CANCER; SURVIVORS; FATIGUE;
   ABILITY; ABSENCE; CARE
AB Objective: One key aspect of cancer survivorship is return-to-work. Unfortunately, many cancer survivors face problems upon their return-to-work. For that reason, we developed a hospital-based work support intervention aimed at enhancing return-to-work. We studied effectiveness of the intervention compared to usual care for female cancer patients in a multi-centre randomised controlled trial.
   Methods: Breast and gynaecological cancer patients who were treated with curative intent and had paid work were randomised to the intervention group (n = 65) or control group (n = 68). The intervention involved patient education and support at the hospital and improvement of communication between treating and occupational physicians. In addition, we asked patient's occupational physician to organise a meeting with the patient and the supervisor to make a concrete gradual return-to-work plan. Outcomes at 12 months of follow-up included rate and time until return-to-work (full or partial), quality of life, work ability, work functioning, and lost productivity costs. Time until return-to-work was analyzed with Kaplan-Meier survival analysis.
   Results: Return-to-work rates were 86% and 83% (p = 0.6) for the intervention group and control group when excluding 8 patients who died or with a life expectancy of months at follow-up. Median time from initial sick leave to partial return-to-work was 194 days (range 14-435) versus 192 days (range 82-465) (p = 0.90) with a hazard ratio of 1.03 (95% CI 0.64-1.6). Quality of life and work ability improved statistically over time but did not differ statistically between groups. Work functioning and costs did not differ statistically between groups.
   Conclusion: The intervention was easily implemented into usual psycho-oncological care and showed high return-to-work rates. We failed to show any differences between groups on return-to-work outcomes and quality of life scores. Further research is needed to study which aspects of the intervention are useful and which elements need improvement.
C1 [Tamminga, Sietske J.; Verbeek, Jos H. A. M.; Frings-Dresen, Monique H. W.; de Boer, Angela G. E. M.] Univ Amsterdam, Acad Med Ctr, Coronel Inst Occupat Hlth, NL-1105 AZ Amsterdam, Netherlands.
   [Verbeek, Jos H. A. M.] Finnish Inst Occupat Hlth, Kuopio, Finland.
   [Bos, Monique M. E. M.] Reinier de Graaf Groep, Dept Internal Med, Delft, Netherlands.
   [Fons, Guus] Univ Amsterdam, Acad Med Ctr, Dept Gynaecol, NL-1105 AZ Amsterdam, Netherlands.
   [Kitzen, Jos J. E. M.] Albert Schweitzer Hosp, Dept Internal Med, Dordrecht, Netherlands.
   [Plaisier, Peter W.] Albert Schweitzer Hosp, Dept Surg, Dordrecht, Netherlands.
RP Tamminga, SJ (reprint author), Univ Amsterdam, Acad Med Ctr, Coronel Inst Occupat Hlth, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
EM S.J.Tamminga@amc.uva.nl
RI Verbeek, Jos/F-8382-2013
OI Verbeek, Jos/0000-0002-6537-6100
FU Stichting Insituut Gak
FX The study was granted by the Stichting Insituut Gak and is part of the
   research program "Pathways to work'' (www.verbeteronderzoek.nl). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3
   Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012
   Anema JR, 2009, J OCCUP REHABIL, V19, P419, DOI 10.1007/s10926-009-9202-3
   BOSSCHER RJ, 1997, NEDERLANDS TIJDSCHRI, V0052
   Bouwmans C, 2010, MANUAL COST STUDIES
   Cameron L, 2008, SUPPORT CARE CANCER, V17, P1057, DOI [10.1007/s00520-008-0540-z, DOI 10.1007/S00520-008-0540-Z]
   de Boer AGEM, 2008, BRIT J CANCER, V98, P1342, DOI 10.1038/sj.bjc.6604302
   de Boer AGEM, 2009, JAMA-J AM MED ASSOC, V301, P753, DOI 10.1001/jama.2009.187
   Drolet M, 2005, CAN MED ASSOC J, V173, P765, DOI 10.1503/cmaj.050178
   DUPONT WD, 2009, PS POWER SAMPLE SIZE
   Feuerstein M, 2011, COCHRANE DATABASE SY, V2
   Feuerstein M, 2007, J OCCUP ENVIRON MED, V49, P803, DOI 10.1097/JOM.0b013e318095a458
   Fleer J, 2006, SUPPORT CARE CANCER, V14, P251, DOI 10.1007/s00520-005-0879-3
   Hansen JA, 2008, J OCCUP ENVIRON MED, V50, P777, DOI 10.1097/JOM.0b013e318165159e
   ILMARINEN J, 1992, SCAND J WORK ENV HEA, V18, P8
   Koopmans PC, 2008, OCCUP ENVIRON MED, V65, P494, DOI 10.1136/oem.2007.034322
   Lerner D, 2001, MED CARE, V39, P72, DOI 10.1097/00005650-200101000-00009
   Maunsell E, 1999, PSYCHO-ONCOLOGY, V8, P467, DOI 10.1002/(SICI)1099-1611(199911/12)8:6<467::AID-PON400>3.0.CO;2-P
   Mols F, 2005, EUR J CANCER, V41, P2613, DOI 10.1016/j.ejca.2005.05.017
   Mols F, 2009, PSYCHO-ONCOLOGY, V18, P1252, DOI 10.1002/pon.1522
   Nieuwenhuijsen K, 2006, J OCCUP REHABIL, V16, P647, DOI 10.1007/s10926-006-9057-9
   Oeffinger KC, 2006, J CLIN ONCOL, V24, P5117, DOI 10.1200/JCO2006.07.0474
   Peteet JR, 2000, GEN HOSP PSYCHIAT, V22, P200, DOI 10.1016/S0163-8343(00)00076-1
   Petrie KJ, 1996, BRIT MED J, V312, P1191
   Pryce J, 2007, J OCCUP REHABIL, V17, P83, DOI 10.1007/s10926-006-9040-5
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Satagopan JM, 2004, BRIT J CANCER, V91, P1229, DOI 10.1038/sj.bjc.6602102
   Schellings R, 2009, J CLIN EPIDEMIOL, V62, P393, DOI 10.1016/j.jclinepi.2008.07.010
   Scrucca L, 2007, BONE MARROW TRANSPL, V40, P381, DOI 10.1038/sj.bmt.1705727
   SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O
   Spelten ER, 2003, EUR J CANCER, V39, P1562, DOI 10.1016/S0959-8049(03)00364-2
   Spelten ER, 2002, PSYCHO-ONCOL, V11, P124, DOI 10.1002/pon.585
   Tamminga SJ, 2012, J OCCUP REHABIL, V22, P565, DOI 10.1007/s10926-012-9372-2
   Tamminga SJ, 2010, OCCUP ENVIRON MED, V67, P639, DOI 10.1136/oem.2009.050070
   Tamminga SJ, 2012, SCAND J WORK ENV HEA, V38, P144, DOI 10.5271/sjweh.3199
   Tamminga SJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-345
   Taskila T, 2006, SUPPORT CARE CANCER, V14, P427, DOI 10.1007/s00520-005-0005-6
   van Veldhoven MMT, 2002, MANUAL QEUSTIONNAIRE
   Verbeek J, 2007, HDB CANC SURVIVORSHI, P381
NR 39
TC 24
Z9 24
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 22
PY 2013
VL 8
IS 5
AR e63271
DI 10.1371/journal.pone.0063271
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 163UP
UT WOS:000320362700013
PM 23717406
OA Green Published, Other Gold
DA 2019-05-24
ER

PT J
AU Frimodt-Moller, M
   Kamper, AL
   Strandgaard, S
   Kreiner, S
   Nielsen, AH
AF Frimodt-Moller, Marie
   Kamper, Anne-Lise
   Strandgaard, Svend
   Kreiner, Svend
   Nielsen, Arne Hoj
TI Beneficial Effects on Arterial Stiffness and Pulse-Wave Reflection of
   Combined Enalapril and Candesartan in Chronic Kidney Disease - A
   Randomized Trial
SO PLOS ONE
LA English
DT Article
ID STAGE RENAL-DISEASE; CONVERTING-ENZYME-INHIBITOR;
   GLOMERULAR-FILTRATION-RATE; CENTRAL AORTIC PRESSURE; CENTRAL
   BLOOD-PRESSURE; CARDIOVASCULAR EVENTS; RECEPTOR BLOCKADE;
   ACE-INHIBITION; HIGH-RISK; VELOCITY
AB Background: Cardiovascular disease (CVD) is highly prevalent in patients with chronic kidney disease (CKD). Inhibition of the renin-angiotensinsystem (RAS) in hypertension causes differential effects on central and brachial blood pressure (BP), which has been translated into improved outcome. The objective was to examine if a more complete inhibition of RAS by combining an angiotensin converting enzyme inhibitor (ACEI) and an angiotensin receptor antagonist (ARB) compared to monotherapy has an additive effect on central BP and pulse-wave velocity (PWV), which are known markers of CVD.
   Methods: Sixty-seven CKD patients (mean GFR 30, range 13-59 ml/min/1.73 m(2)) participated in an open randomized study of 16 weeks of monotherapy with either enalapril or candesartan followed by 8 weeks of dual blockade aiming at a total dose of 16 mg candesartan and 20 mg enalapril o.d. Pulse-wave measurements were performed at week 0, 8, 16 and 24 by the SphygmoCor device.
   Results: Significant additive BP independent reductions were found after dual blockade in aortic PWV (20.3 m/s, P<0.05) and in augmentation index (22%, P<0.01) compared to monotherapy. Furthermore pulse pressure amplification was improved (P<0.05) and central systolic BP reduced (26 mmHg, P<0.01).
   Conclusions: Dual blockade of the RAS resulted in an additive BP independent reduction in pulse-wave reflection and arterial stiffness compared to monotherapy in CKD patients.
C1 [Frimodt-Moller, Marie; Kamper, Anne-Lise] Univ Copenhagen, Rigshosp, Dept Nephrol, DK-2100 Copenhagen, Denmark.
   [Strandgaard, Svend; Nielsen, Arne Hoj] Herlev Hosp, Copenhagen, Denmark.
   [Kreiner, Svend] Univ Copenhagen, Dept Biostat, DK-2100 Copenhagen, Denmark.
RP Frimodt-Moller, M (reprint author), Univ Copenhagen, Rigshosp, Dept Nephrol, DK-2100 Copenhagen, Denmark.
EM mariefm@dadlnet.dk
FU Danish Kidney Association (Nyreforeningen); Danish Society of
   Nephrology; Danish Heart Association; Research Council of Herlev
   Hospital; Foundation of Augustinus; Foundation of Horslev; Foundation of
   Aase; Foundation of Ejnar Danielsen; Aase Bay, Denmark
FX This work is funded by the Danish Kidney Association (Nyreforeningen),
   the Danish Society of Nephrology, The Danish Heart Association, the
   Research Council of Herlev Hospital, the Foundations of Augustinus,
   Horslev, Aase and Ejnar Danielsen and Aase Bay, Denmark. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012
   Anan F, 2005, EUR J CLIN PHARMACOL, V61, P353, DOI 10.1007/s00228-005-0931-8
   Avolio AP, 2009, HYPERTENSION, V54, P375, DOI 10.1161/HYPERTENSIONAHA.109.134379
   Bakris GL, 2000, ARCH INTERN MED, V160, P685, DOI 10.1001/archinte.160.5.685
   Blacher J, 1999, CIRCULATION, V99, P2434, DOI 10.1161/01.CIR.99.18.2434
   Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161
   BROCHNER.J, 1972, SCAND J CLIN LAB INV, V30, P271, DOI 10.3109/00365517209084290
   BROCHNERMORTENSEN J, 1981, SCAND J CLIN LAB INV, V41, P91, DOI 10.3109/00365518109092020
   Chan KE, 2011, KIDNEY INT, V80, P978, DOI 10.1038/ki.2011.228
   Covic A, 2005, J NEPHROL, V18, P388
   Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3
   Dhakam Z, 2006, AM J HYPERTENS, V19, P214, DOI 10.1016/j.amjhyper.2005.08.007
   Frimodt-Moller M, 2006, SCAND J CLIN LAB INV, V66, P385, DOI 10.1080/00365510600731332
   FRIMODTMOLLER MHN, 2009, NEPHROL DIAL TRANSPL
   Gallagher D, 2004, AM J HYPERTENS, V17, P1059, DOI 10.1016/j.amjhyper.2004.05.027
   Hirata K, 2005, J HYPERTENS, V23, P551, DOI 10.1097/01.hjh.0000160211.56103.48
   KAMPER AL, 1990, SCAND J UROL NEPHROL, V24, P69, DOI 10.3109/00365599009180363
   Laurent S, 2006, EUR HEART J, V27, P2588, DOI 10.1093/eurheartj/ehl254
   Lemogoum D, 2004, J HYPERTENS, V22, P511, DOI 10.1097/01.hjh.0000098265.58662.94
   London GM, 2001, HYPERTENSION, V38, P434, DOI 10.1161/01.HYP.38.3.434
   LONDON GM, 1994, CIRCULATION, V90, P2786, DOI 10.1161/01.CIR.90.6.2786
   Mahmud A, 2000, J HUM HYPERTENS, V14, P541, DOI 10.1038/sj.jhh.1001053
   Mahmud A, 2002, AM J HYPERTENS, V15, P321, DOI 10.1016/S0895-7061(01)02313-5
   National Kidney Foundation, 2002, AM J KIDNEY DIS S, V39, pS1, DOI DOI 10.1053/AJKD.2002.30571.PUBMED:11904577
   Nichols WW, 2008, J CLIN HYPERTENS, V10, P295, DOI 10.1111/j.1751-7176.2008.04746.x
   Palmer BF, 2004, NEW ENGL J MED, V351, P585, DOI 10.1056/NEJMra035279
   Pannier B, 2005, HYPERTENSION, V45, P592, DOI 10.1161/01.HYP.0000159190.71253.c3
   Pauca AL, 2001, HYPERTENSION, V38, P932, DOI 10.1161/hy1001.096106
   Pini R, 2008, J AM COLL CARDIOL, V51, P2432, DOI 10.1016/j.jacc.2008.03.031
   Poulter NR, 2005, LANCET, V366, P907, DOI 10.1016/S0140-6736(05)67186-3
   Protogerou AD, 2009, CURR PHARM DESIGN, V15, P267, DOI 10.2174/138161209787354267
   Roman MJ, 2007, HYPERTENSION, V50, P197, DOI 10.1161/HYPERTENSIONAHA.107.089078
   Safar ME, 2002, HYPERTENSION, V39, P735, DOI 10.1161/hy0202.098325
   Sleight P, 2001, LANCET, V358, P2130, DOI 10.1016/S0140-6736(01)07186-0
   Wang KL, 2009, J HYPERTENS, V27, P461, DOI 10.1097/HJH.0b013e3283220ea4
   Weber T, 2009, J HYPERTENS, V27, P1624, DOI 10.1097/HJH.0b013e32832cb04e
   Williams B, 2006, CIRCULATION, V113, P1213, DOI 10.1161/CIRCULATIONAHA.105.595496
   Yusuf S, 2000, NEW ENGL J MED, V342, P145
   Yusuf S, 2008, NEW ENGL J MED, V358, P1547, DOI 10.1056/NEJMoa0801317
NR 39
TC 27
Z9 29
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 31
PY 2012
VL 7
IS 7
AR e41757
DI 10.1371/journal.pone.0041757
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 982LS
UT WOS:000307045600041
PM 22860014
OA Other Gold, Green Published
DA 2019-05-24
ER

PT J
AU Hoogeboom, TJ
   Oosting, E
   Vriezekolk, JE
   Veenhof, C
   Siemonsma, PC
   de Bie, RA
   van den Ende, CHM
   van Meeteren, NLU
AF Hoogeboom, Thomas J.
   Oosting, Ellen
   Vriezekolk, Johanna E.
   Veenhof, Cindy
   Siemonsma, Petra C.
   de Bie, Rob A.
   van den Ende, Cornelia H. M.
   van Meeteren, Nico L. U.
TI Therapeutic Validity and Effectiveness of Preoperative Exercise on
   Functional Recovery after Joint Replacement: A Systematic Review and
   Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID QUALITY-OF-LIFE; TOTAL KNEE ARTHROPLASTY; TOTAL HIP-REPLACEMENT; PATIENT
   CHARACTERISTICS; RANDOMIZED-TRIALS; CONSORT STATEMENT;
   PHYSICAL-ACTIVITY; EFFECT SIZE; SURGERY; OSTEOARTHRITIS
AB Background: Our aim was to develop a rating scale to assess the therapeutic validity of therapeutic exercise programmes. By use of this rating scale we investigated the therapeutic validity of therapeutic exercise in patients awaiting primary total joint replacement (TJR). Finally, we studied the association between therapeutic validity of preoperative therapeutic exercise and its effectiveness in terms of postoperative functional recovery.
   Methods: (Quasi) randomised clinical trials on preoperative therapeutic exercise in adults awaiting TJR on postoperative recovery of functioning within three months after surgery were identified through database and reference screening. Two reviewers extracted data and assessed the risk of bias and therapeutic validity. Therapeutic validity of the interventions was assessed with a nine-itemed, expert-based rating scale (scores range from 0 to 9; score >= 6 reflecting therapeutic validity), developed in a four-round Delphi study. Effects were pooled using a random-effects model and meta-regression was used to study the influence of therapeutic validity.
   Results: Of the 7,492 articles retrieved, 12 studies (737 patients) were included. None of the included studies demonstrated therapeutic validity and two demonstrated low risk of bias. Therapeutic exercise was not associated with 1) observed functional recovery during the hospital stay (Standardised Mean Difference [SMD]: -1.19; 95%-confidence interval [CI], -2.46 to 0.08); 2) observed recovery within three months of surgery (SMD: -0.15; 95%-CI, -0.42 to 0.12); and 3) self-reported recovery within three months of surgery (SMD -0.07; 95%-CI, -0.35 to 0.21) compared with control participants. Meta-regression showed no statistically significant relationship between therapeutic validity and pooled-effects.
   Conclusion: Preoperative therapeutic exercise for TJR did not demonstrate beneficial effects on postoperative functional recovery. However, poor therapeutic validity of the therapeutic exercise programmes may have hampered potentially beneficial effects, since none of the studies met the predetermined quality criteria. Future review studies on therapeutic exercise should address therapeutic validity.
C1 [Hoogeboom, Thomas J.; Vriezekolk, Johanna E.; van den Ende, Cornelia H. M.] Sint Maartensklin, Dept Rheumatol, Nijmegen, Netherlands.
   [Hoogeboom, Thomas J.; de Bie, Rob A.] Maastricht Univ, Sch Publ Hlth & Primary Care Caphri, Dept Epidemiol, Maastricht, Netherlands.
   [Oosting, Ellen] Gelderse Vallei Hosp, Dept Physiotherapy, Ede, Netherlands.
   [Veenhof, Cindy] NIVEL, Dept Allied Hlth Care, Utrecht, Netherlands.
   [Siemonsma, Petra C.] TNO, Expertise Ctr Life Style, Leiden, Netherlands.
   [van Meeteren, Nico L. U.] TNO, Innovat Area Healthy Life, Leiden, Netherlands.
   [van Meeteren, Nico L. U.] Ctr Care Technol Res, Maastricht, Netherlands.
RP Hoogeboom, TJ (reprint author), Sint Maartensklin, Dept Rheumatol, Nijmegen, Netherlands.
EM thomashoogeboom@gmail.com
RI van den Ende, Cornelia/G-9559-2011; Vriezekolk, Johanna/J-8684-2016;
   Hoogeboom, Thomas/G-8767-2015
OI van den Ende, Cornelia/0000-0002-4352-2824; Hoogeboom,
   Thomas/0000-0003-2103-419X
FU Ministry of Health, The Netherlands
FX This study was funded by the Ministry of Health, The Netherlands. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Ackerman IN, 2004, AUST J PHYSIOTHER, V50, P25, DOI 10.1016/S0004-9514(14)60245-2
   Ainsworth BE, 2011, MED SCI SPORT EXER, V43, P1575, DOI 10.1249/MSS.0b013e31821ece12
   Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012
   Anderson JG, 1996, J ARTHROPLASTY, V11, P831, DOI 10.1016/S0883-5403(96)80183-5
   Barbay K, 2009, ORTHOP NURS, V28, P127, DOI 10.1097/NOR.0b013e3181a46a09
   Beaupre LA, 2004, J RHEUMATOL, V31, P1166
   Boule NG, 2001, JAMA-J AM MED ASSOC, V286, P1218, DOI 10.1001/jama.286.10.1218
   Boutron I, 2008, ANN INTERN MED, V148, P295, DOI 10.7326/0003-4819-148-4-200802190-00008
   Chinn S, 2000, STAT MED, V19, P3127, DOI 10.1002/1097-0258(20001130)19:22<3127::AID-SIM784>3.3.CO;2-D
   Chodzko-Zajko WJ, 2009, MED SCI SPORT EXER, V41, P1510, DOI 10.1249/MSS.0b013e3181a0c95c
   Coudeyre E., 2007, Annales de Readaptation et de Medecine Physique, V50, P189, DOI 10.1016/j.annrmp.2007.02.002
   Craig P, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1655
   Daanen HA, 2012, INT J SPORTS PH 0215
   Dauty M, 2007, Ann Readapt Med Phys, V50, P462, DOI 10.1016/j.annrmp.2007.04.012
   Ditmyer Marcia M, 2002, Orthop Nurs, V21, P43
   DLima DD, 1996, CLIN ORTHOP RELAT R, P174
   Escobar A, 2007, RHEUMATOLOGY, V46, P112, DOI 10.1093/rheumatology/kel184
   Evgeniadis G, 2008, J BACK MUSCULOSKELET, V21, P161, DOI 10.3233/BMR-2008-21303
   Ewald FC, 1999, J ARTHROPLASTY, V14, P473, DOI 10.1016/S0883-5403(99)90104-3
   Ferrara PE, 2008, CLIN REHABIL, V22, P977, DOI 10.1177/0269215508094714
   Fitz Gerald JD, 2004, ARTHRIT RHEUM-ARTHR, V51, P100, DOI 10.1002/art.20090
   Gilbey HJ, 2003, CLIN ORTHOP RELAT R, P193, DOI 10.1097/01.blo.0000053168.71678.2b
   Glasziou P, 2005, BMJ-BRIT MED J, V330, P644, DOI 10.1136/bmj.330.7492.644
   Gocen Z, 2004, CLIN REHABIL, V18, P353, DOI 10.1191/0269215504cr758oa
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1277, DOI 10.1016/j.jclinepi.2011.01.011
   Hawker GA, 2006, CURR OPIN RHEUMATOL, V18, P526
   Herbert RD, 2005, BRIT MED J, V331, P507, DOI 10.1136/bmj.331.7515.507
   Hoeksma HL, 2005, RHEUMATOLOGY, V44, P461, DOI 10.1093/rheumatology/keh482
   Hollis S, 1999, BRIT MED J, V319, P670, DOI 10.1136/bmj.319.7211.670
   Hoogeboom TJ, 2009, OSTEOARTHR CARTILAGE, V17, P1420, DOI 10.1016/j.joca.2009.05.008
   Hoogeboom TJ, 2010, CLIN REHABIL, V24, P901, DOI 10.1177/0269215510371427
   Hulzebos EHJ, 2006, JAMA-J AM MED ASSOC, V296, P1851, DOI 10.1001/jama.296.15.1851
   JACK S, 2011, CLIN ANAESTHESIOL, V25, P461
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Kennedy LG, 2003, KNEE, V10, P161, DOI 10.1016/S0968-0160(02)00138-2
   Kettunen JA, 2004, SCAND J MED SCI SPOR, V14, P138, DOI 10.1111/j.1600-0838.2004.0396.x
   Kraemer WJ, 2002, MED SCI SPORT EXER, V34, P364
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   Lingard EA, 2004, J BONE JOINT SURG AM, V86A, P2179, DOI 10.2106/00004623-200410000-00008
   Liu CK, 2011, CLIN GERIATR MED, V27, P101, DOI 10.1016/j.cger.2010.08.001
   Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3
   Mahomed NN, 2002, J RHEUMATOL, V29, P1273
   McGinn TG, 2000, JAMA-J AM MED ASSOC, V284, P79, DOI 10.1001/jama.284.1.79
   Moher D, 2015, SYST REV, V4, DOI [10.1186/2046-4053-4-1, 10.1136/bmj.b2535]
   Pasquina P, 2003, BRIT MED J, V327, P1379, DOI 10.1136/bmj.327.7428.1379
   Robinson KA, 2002, INT J EPIDEMIOL, V31, P150, DOI 10.1093/ije/31.1.150
   Rodgers JA, 1998, J ARTHROPLASTY, V13, P414, DOI 10.1016/S0883-5403(98)90007-9
   Rooks DS, 2006, ARTHRIT RHEUM-ARTHR, V55, P700, DOI 10.1002/art.22223
   Santaguida PL, 2008, CAN J SURG, V51, P428
   Schmidt H, 2010, MED LAW, V29, P565
   Sutton AJ, 2000, BRIT MED J, V320, P1574, DOI 10.1136/bmj.320.7249.1574
   Topp R, 2009, PM&R, V1, P729, DOI 10.1016/j.pmrj.2009.06.003
   Umpierre D, 2011, JAMA-J AM MED ASSOC, V305, P1790, DOI 10.1001/jama.2011.576
   Valkenet K, 2011, CLIN REHABIL, V25, P99, DOI 10.1177/0269215510380830
   van Rijn RM, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5688
   van Tulder MW, 2009, SPINE, V34, P1685, DOI 10.1097/BRS.0b013e3181ab6a78
   Veenhof C, 2007, INT J BEHAV MED, V14, P86, DOI 10.1007/BF03004173
   Wallis JA, 2011, OSTEOARTHR CARTILAGE, V19, P1381, DOI 10.1016/j.joca.2011.09.001
   WEIDENHIELM L, 1993, SCAND J REHABIL MED, V25, P25
   Williamson L, 2007, RHEUMATOLOGY, V46, P1445, DOI 10.1093/rheumatology/kem119
   Wright AA, 2011, PHYS THER, V91, P510, DOI 10.2522/ptj.20100171
   Wylde V, 2007, KNEE, V14, P417, DOI 10.1016/j.knee.2007.06.001
   Yates SL, 2005, PAIN, V117, P314, DOI 10.1016/j.pain.2005.06.018
   Zeni JA, 2010, J BONE JOINT SURG AM, V92A, P1130, DOI 10.2106/JBJS.I.00299
NR 65
TC 72
Z9 72
U1 0
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 31
PY 2012
VL 7
IS 5
AR e38031
DI 10.1371/journal.pone.0038031
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959TY
UT WOS:000305338500076
PM 22675429
OA Green Published, Other Gold
DA 2019-05-24
ER

PT J
AU Chu, R
   Walter, SD
   Guyatt, G
   Devereaux, PJ
   Walsh, M
   Thorlund, K
   Thabane, L
AF Chu, Rong
   Walter, Stephen D.
   Guyatt, Gordon
   Devereaux, P. J.
   Walsh, Michael
   Thorlund, Kristian
   Thabane, Lehana
TI Assessment and Implication of Prognostic Imbalance in Randomized
   Controlled Trials with a Binary Outcome - A Simulation Study
SO PLOS ONE
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; INCREASES STATISTICAL POWER; ACUTE
   ISCHEMIC-STROKE; COVARIATE ADJUSTMENT; CLINICAL-TRIALS; SAMPLE-SIZE;
   CONSORT STATEMENT; PROPENSITY SCORE; ODDS RATIOS; REGRESSION
AB Background: Chance imbalance in baseline prognosis of a randomized controlled trial can lead to over or underestimation of treatment effects, particularly in trials with small sample sizes. Our study aimed to (1) evaluate the probability of imbalance in a binary prognostic factor (PF) between two treatment arms, (2) investigate the impact of prognostic imbalance on the estimation of a treatment effect, and (3) examine the effect of sample size (n) in relation to the first two objectives.
   Methods: We simulated data from parallel-group trials evaluating a binary outcome by varying the risk of the outcome, effect of the treatment, power and prevalence of the PF, and n. Logistic regression models with and without adjustment for the PF were compared in terms of bias, standard error, coverage of confidence interval and statistical power.
   Results: For a PF with a prevalence of 0.5, the probability of a difference in the frequency of the PF >= 5% reaches 0.42 with 125/arm. Ignoring a strong PF (relative risk = 5) leads to underestimating the strength of a moderate treatment effect, and the underestimate is independent of n when n is >50/arm. Adjusting for such PF increases statistical power. If the PF is weak (RR = 2), adjustment makes little difference in statistical inference. Conditional on a 5% imbalance of a powerful PF, adjustment reduces the likelihood of large bias. If an absolute measure of imbalance >= 5% is deemed important, including 1000 patients/arm provides sufficient protection against such an imbalance. Two thousand patients/arm may provide an adequate control against large random deviations in treatment effect estimation in the presence of a powerful PF.
   Conclusions: The probability of prognostic imbalance in small trials can be substantial. Covariate adjustment improves estimation accuracy and statistical power, and hence should be performed when strong PFs are observed.
C1 [Chu, Rong; Walter, Stephen D.; Guyatt, Gordon; Devereaux, P. J.; Walsh, Michael; Thorlund, Kristian; Thabane, Lehana] McMaster Univ, Dept Clin Epidemiol & Biostat, Fac Hlth Sci, Hamilton, ON, Canada.
   [Devereaux, P. J.; Thabane, Lehana] Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada.
   [Thabane, Lehana] St Josephs Healthcare Hamilton, Biostat Unit, Father Sean OSullivan Res Ctr, Hamilton, ON, Canada.
   [Thabane, Lehana] St Josephs Healthcare Hamilton, Ctr Evaluat Med, Hamilton, ON, Canada.
RP Chu, R (reprint author), McMaster Univ, Dept Clin Epidemiol & Biostat, Fac Hlth Sci, Hamilton, ON, Canada.
EM chur@mcmaster.ca
OI Walsh, Michael/0000-0001-8292-2014; Devereaux, P.J./0000-0003-2935-637X
FU Canadian Institutes of Health Research (CIHR); Canadian Network and
   Centre for Trials Internationally (CANNeCTIN)
FX Rong Chu is a recipient of the Canadian Institutes of Health Research
   (CIHR) Doctoral Research Award. http://www.cihr.ca/ The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.; We thank the anonymous reviewers for
   their constructive comments that helped to strengthen the manuscript.
   Rong Chu holds a doctoral research award from the Canadian Institutes of
   Health Research. This work was partially supported by a research grant
   from the Canadian Network and Centre for Trials Internationally
   (CANNeCTIN).
CR Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012
   Austin PC, 2010, J CLIN EPIDEMIOL, V63, P142, DOI 10.1016/j.jclinepi.2009.06.002
   Brower RG, 2004, NEW ENGL J MED, V351, P327
   Chan AW, 2005, LANCET, V365, P1159, DOI 10.1016/S0140-6736(05)71879-1
   Charles P, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1732
   Ciolino J, 2011, CONTEMP CLIN TRIALS, V32, P250, DOI 10.1016/j.cct.2010.11.005
   Cui Lu, 2002, J Biopharm Stat, V12, P347, DOI 10.1081/BIP-120014565
   Demchuk AM, 2001, NEUROLOGY, V57, P474, DOI 10.1212/WNL.57.3.474
   Dickinson K, 2000, BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308
   Dodge Y., 2003, OXFORD DICT STAT TER
   FLURY BK, 1986, AM STAT, V40, P249, DOI 10.2307/2684560
   GAIL MH, 1984, BIOMETRIKA, V71, P431
   Greenland S, 1999, STAT SCI, V14, P29
   Grouin JM, 2004, STAT MED, V23, P701
   Guyatt GH, 2000, JAMA-J AM MED ASSOC, V284, P1290, DOI 10.1001/jama.284.10.1290
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P380, DOI 10.1016/j.jclinepi.2010.09.011
   Hauck WW, 1998, CONTROL CLIN TRIALS, V19, P249, DOI 10.1016/S0197-2456(97)00147-5
   HAUCK WW, 1991, J CLIN EPIDEMIOL, V44, P77, DOI 10.1016/0895-4356(91)90203-L
   Hernandez AV, 2004, J CLIN EPIDEMIOL, V57, P454, DOI 10.1016/j.jclinepi.2003.09.014
   International Conference on Harmonisation, 1999, STAT MED, V18, P1905
   Keen HI, 2005, J RHEUMATOL, V32, P2083
   Lingsma H, 2010, J CLIN EPIDEMIOL, V63, P1391, DOI 10.1016/j.jclinepi.2010.05.003
   MARLER JR, 1995, NEW ENGL J MED, V333, P1581
   Meade MO, 2008, JAMA-J AM MED ASSOC, V299, P637, DOI 10.1001/jama.299.6.637
   MOHER D, 1994, JAMA-J AM MED ASSOC, V272, P122, DOI 10.1001/jama.272.2.122
   Negassa A, 2007, CONTEMP CLIN TRIALS, V28, P242, DOI 10.1016/j.cct.2006.08.007
   Pocock SJ, 2002, STAT MED, V21, P2917, DOI 10.1002/sim.1296
   Robinson LD, 1991, INT STAT REV, V58, P227
   ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398
   ROSENBAUM PR, 1985, AM STAT, V39, P33, DOI 10.2307/2683903
   SENN S, 1994, STAT MED, V13, P1715, DOI 10.1002/sim.4780131703
   WALTER SD, 1985, STAT MED, V4, P437, DOI 10.1002/sim.4780040405
   Wang SJ, 2010, CLIN TRIALS, V7, P525, DOI 10.1177/1740774510375455
   Yu LM, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-59
   ZELEN M, 1974, J CHRON DIS, V27, P365, DOI 10.1016/0021-9681(74)90015-0
NR 35
TC 14
Z9 14
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 22
PY 2012
VL 7
IS 5
AR e36677
DI 10.1371/journal.pone.0036677
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959VQ
UT WOS:000305345300010
PM 22629322
OA DOAJ Gold, Green Published
DA 2019-05-24
ER

PT J
AU Li, XQ
   Tao, KM
   Zhou, QH
   Moher, D
   Chen, HY
   Wang, FZ
   Ling, CQ
AF Li, Xiao-qian
   Tao, Kun-ming
   Zhou, Qing-hui
   Moher, David
   Chen, Hong-yun
   Wang, Fu-zhe
   Ling, Chang-quan
TI Endorsement of the CONSORT Statement by High-Impact Medical Journals in
   China: A Survey of Instructions for Authors and Published Papers
SO PLOS ONE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIALS; QUALITY; EDITORS
AB Background: The CONSORT Statement is a reporting guideline for authors when reporting randomized controlled trials (RCTs). It offers a standard way for authors to prepare RCT reports. It has been endorsed by many high-impact medical journals and by international editorial groups. This study was conducted to assess the endorsement of the CONSORT Statement by high-impact medical journals in China by reviewing their instructions for authors.
   Methodology/Principal Findings: A total of 200 medical journals were selected according to the Chinese Science and Technology Journal Citation Reports, 195 of which publish clinical research papers. Their instructions for authors were reviewed and all texts mentioning the CONSORT Statement or CONSORT extension papers were extracted. Any mention of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (URM) developed by the International Committee of Medical Journal Editors (ICMJE) or 'clinical trial registration' was also extracted. For journals endorsing the CONSORT Statement, their most recently published RCT reports were retrieved and evaluated to assess whether the journals have followed what the CONSORT Statement required. Out of the 195 medical journals publishing clinical research papers, only six (6/195, 3.08%) mentioned 'CONSORT' in their instructions for authors; out of the 200 medical journals surveyed, only 14 (14/200, 7.00%) mentioned 'ICMJE' or 'URM' in their instructions for authors, and another five journals stated in their instructions for authors that clinical trials should have trial registration numbers and that priority would be given to clinical trials which had been registered. Among the 62 RCT reports published in the six journals endorsing the CONSORT Statement, 20 (20/62, 32.26%) contained flow diagrams and only three (3/62, 4.84%) provided trial registration information.
   Conclusions/Significance: Medical journals in China endorsing either the CONSORT Statement or the ICMJE's URM constituted a small percentage of the total; all of these journals used ambiguous language regarding what was expected of authors.
C1 [Li, Xiao-qian; Zhou, Qing-hui; Chen, Hong-yun; Wang, Fu-zhe; Ling, Chang-quan] Second Mil Med Univ, Changhai Hosp, Dept Tradit Chinese Med, Shanghai, Peoples R China.
   [Tao, Kun-ming] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Anesthesiol, Shanghai, Peoples R China.
   [Moher, David] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada.
   [Ling, Chang-quan] Shanghai Univ Tradit Chinese Med, E Inst Tradit Chinese Internal Med, Shanghai Municipal Educ Commiss, Shanghai, Peoples R China.
RP Li, XQ (reprint author), Second Mil Med Univ, Changhai Hosp, Dept Tradit Chinese Med, Shanghai, Peoples R China.
EM zhouqinghui@sohu.com; lingchangquan@gmail.com
RI Ling, Changquan/J-2108-2016; Moher, David/I-3408-2019
OI Ling, Changquan/0000-0003-3476-6445; Moher, David/0000-0003-2434-4206;
   Ling, Changquan/0000-0002-0037-4059
FU E-Institutes of Shanghai Municipal Education Commission [E03008]
FX This work was partly supported by the E-Institutes of Shanghai Municipal
   Education Commission (No. E03008). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Adams J., 2009, GLOBAL RES REPORT CH
   Adams J, 2010, GLOBAL RES REPORT US
   Altman DG, 2005, BRIT MED J, V330, P1056, DOI 10.1136/bmj.330.7499.1056
   Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012
   Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637
   Davidoff Frank, 2003, J Am Osteopath Assoc, V103, P137
   De Angelis C, 2004, LANCET, V364, P911, DOI 10.1016/S0140-6736(04)17034-7
   Egger M, 2001, JAMA-J AM MED ASSOC, V285, P1996, DOI 10.1001/jama.285.15.1996
   Hopewell S, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-20
   Institute of Science and Technical Information of China, 2010, CHIN SCI TECHN J CIT
   International Committee of Medical Journal, 2010, J CHIN INTEGR UNPUB, V8, P1101
   International Committee of Medical Journal, 2009, J CHIN INTEGR UNPUB, V7, P295
   International Committee of Medical Journal, 2010, J CHIN INTEGR UNPUB, V8, P901
   International Committee of Medical Journal, 2009, J CHIN INTEGR UNPUB, V7, P195
   International Committee of Medical Journal, 2010, J CHIN INTEGR UNPUB, V8, P1001
   International Committee of Medical Journal, 2009, J CHIN INTEGR UNPUB, V7, P95
   Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3
   Moher D, 2010, J CHIN INTEGR MED, V8, P701, DOI DOI 10.3736/JCIM20100801
   Moher D, 2005, CHIN J EVID BASED ME, V5, P702
   Moher David, 2010, Zhong Xi Yi Jie He Xue Bao, V8, P601
   Plint AC, 2006, MED J AUSTRALIA, V185, P263
   Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c332
   Schulz Kenneth F, 2010, Zhong Xi Yi Jie He Xue Bao, V8, P604
   Van Spall HGC, 2007, JAMA-J AM MED ASSOC, V297, P1233, DOI 10.1001/jama.297.11.1233
   Wang G, 2007, CLIN THER, V29, P1456, DOI 10.1016/j.clinthera.2007.07.023
   Wright JR, 2006, J CLIN ONCOL, V24, P843, DOI 10.1200/JCO.2005.02.6005
   Xu L, 2008, CONTEMP CLIN TRIALS, V29, P727, DOI 10.1016/j.cct.2008.05.003
   Zhang DL, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-22
NR 28
TC 20
Z9 22
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 13
PY 2012
VL 7
IS 2
AR e30683
DI 10.1371/journal.pone.0030683
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 925BB
UT WOS:000302733900011
PM 22348017
OA Green Published, Other Gold
DA 2019-05-24
ER

PT J
AU Fritz, H
   Kennedy, D
   Fergusson, D
   Fernandes, R
   Cooley, K
   Seely, A
   Sagar, S
   Wong, R
   Seely, D
AF Fritz, Heidi
   Kennedy, Deborah
   Fergusson, Dean
   Fernandes, Rochelle
   Cooley, Kieran
   Seely, Andrew
   Sagar, Stephen
   Wong, Raimond
   Seely, Dugald
TI Selenium and Lung Cancer: A Systematic Review and Meta Analysis
SO PLOS ONE
LA English
DT Review
ID GYNECOLOGIC RADIATION ONCOLOGY; A/J MOUSE LUNG; SODIUM SELENITE;
   PROSTATE-CANCER; METHYLSELENINIC ACID; ORGANOSELENIUM COMPOUND;
   NUTRITIONAL PREVENTION; DIETARY SUPPLEMENTATION; MELANOMA-CELLS; SOLID
   TUMORS
AB Background: Selenium is a natural health product widely used in the treatment and prevention of lung cancers, but large chemoprevention trials have yielded conflicting results. We conducted a systematic review of selenium for lung cancers, and assessed potential interactions with conventional therapies.
   Methods and Findings: Two independent reviewers searched six databases from inception to March 2009 for evidence pertaining to the safety and efficacy of selenium for lung cancers. Pubmed and EMBASE were searched to October 2009 for evidence on interactions with chemo- or radiation-therapy. In the efficacy analysis there were nine reports of five RCTs and two biomarker-based studies, 29 reports of 26 observational studies, and 41 preclinical studies. Fifteen human studies, one case report, and 36 preclinical studies were included in the interactions analysis. Based on available evidence, there appears to be a different chemopreventive effect dependent on baseline selenium status, such that selenium supplementation may reduce risk of lung cancers in populations with lower baseline selenium status (serum, <106 ng/mL), but increase risk of lung cancers in those with higher selenium (>= 121.6 ng/mL). Pooling data from two trials yielded no impact to odds of lung cancer, OR 0.93 (95% confidence interval 0.61-1.43); other cancers that were the primary endpoints of these trials, OR 1.51 (95%CI 0.70-3.24); and all-cause-death, OR 0.93 (95%CI 0.79-1.10). In the treatment of lung cancers, selenium may reduce cisplatin-induced nephrotoxicity and side effects associated with radiation therapy.
   Conclusions: Selenium may be effective for lung cancer prevention among individuals with lower selenium status, but at present should not be used as a general strategy for lung cancer prevention. Although promising, more evidence on the ability of selenium to reduce cisplatin and radiation therapy toxicity is required to ensure that therapeutic efficacy is maintained before any broad clinical recommendations can be made in this context.
C1 [Fritz, Heidi; Kennedy, Deborah; Fernandes, Rochelle; Cooley, Kieran; Seely, Dugald] Canadian Coll Naturopath Med, Dept Res & Epidemiol, Toronto, ON, Canada.
   [Kennedy, Deborah; Cooley, Kieran] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada.
   [Fernandes, Rochelle] Univ Toronto, Lab Med & Pathobiol LMP, Toronto, ON, Canada.
   [Seely, Andrew] Ottawa Hosp Res Inst, Dept Surg, Ottawa, ON, Canada.
   [Sagar, Stephen; Wong, Raimond] McMaster Univ, Juravinski Canc Ctr, Hamilton, ON, Canada.
   [Sagar, Stephen; Wong, Raimond] McMaster Univ, Dept Med, Hamilton, ON, Canada.
RP Fritz, H (reprint author), Canadian Coll Naturopath Med, Dept Res & Epidemiol, Toronto, ON, Canada.
EM dseely@ccnm.edu
RI Cooley, Kieran/L-3080-2019
OI Cooley, Kieran/0000-0001-7960-6504; Fergusson, Dean/0000-0002-3389-2485
FU Canadian Institutes of Health Research (CIHR); SickKids Foundation
FX This project was supported by a knowledge synthesis grant from the
   Canadian Institutes of Health Research (CIHR). DAK is supported by a
   career training award from the SickKids Foundation. No additional
   sources of funding were accessed. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abdulah R, 2005, J TRACE ELEM MED BIO, V19, P141, DOI 10.1016/j.jtemb.2005.09.003
   Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012
   *AM CANC SOC, 2010, CANC REF INF WHAT AR
   Asfour IA, 2007, BIOL TRACE ELEM RES, V120, P1, DOI 10.1007/s12011-007-0029-5
   Ashton K, 2009, AM J CLIN NUTR, V89, p2025S, DOI 10.3945/ajcn.2009.27230F
   Azrak RG, 2008, CANCER BIOL THER, V7, P1901, DOI 10.4161/cbt.7.12.6939
   BALDEW GS, 1989, CANCER RES, V49, P3020
   Becker-Witt C, 2003, J ALTERN COMPLEM MED, V9, P113, DOI 10.1089/107555303321222991
   Bruns F, 2004, MED PRIN PRACT, V13, P185, DOI 10.1159/000078313
   Buntzel J, 2006, TRACE ELEM ELECTROLY, V23, P178
   Buntzel J, 2005, TRACE ELEM ELECTROLY, V22, P211
   Buntzel J, 2002, TRACE ELEM ELECTROLY, V19, P33
   Caffrey PB, 2000, CANCER CHEMOTH PHARM, V46, P74, DOI 10.1007/s002800000127
   Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957
   Combs G F Jr, 1997, Med Klin (Munich), V92 Suppl 3, P42
   Combs GF, 1997, BIOMED ENVIRON SCI, V10, P227
   Das A, 2003, NUTR CANCER, V46, P179, DOI 10.1207/S15327914NC4602_11
   Duffield-Lillico AJ, 2002, CANCER EPIDEM BIOMAR, V11, P630
   El-Bayoumy K, 2002, INT J ONCOL, V20, P557
   El-Bayoumy K, 2006, CARCINOGENESIS, V27, P1369, DOI 10.1093/carcin/bgi328
   Elango N, 2006, CLIN CHIM ACTA, V373, P92, DOI 10.1016/j.cca.2006.05.021
   ELBAYOUMY K, 1993, CARCINOGENESIS, V14, P1111, DOI 10.1093/carcin/14.6.1111
   ElBayoumy K, 1996, ANTICANCER RES, V16, P2709
   Fakih MG, 2008, CANCER CHEMOTH PHARM, V62, P499, DOI 10.1007/s00280-007-0631-4
   Fakih MG, 2006, CLIN CANCER RES, V12, P1237, DOI 10.1158/1078-0432.CCR-05-2004
   Finley JW, 2006, NUTR REV, V64, P146, DOI 10.1301/nr.2006.mar.146-151
   Gagnier JJ, 2006, J CLIN EPIDEMIOL, V59, P1134, DOI 10.1016/j.jclinepi.2005.12.020
   Ganther HE, 2001, ADV EXP MED BIOL, V492, P119
   GARLAND M, 1995, J NATL CANCER I, V87, P497, DOI 10.1093/jnci/87.7.497
   Gonzalez-Moreno O, 2007, INT J CANCER, V121, P1197, DOI 10.1002/ijc.22764
   Goodman GE, 2001, CANCER EPIDEM BIOMAR, V10, P1069
   Hu GZ, 2000, AM J EPIDEMIOL, V151, P975
   Hu HB, 2005, CLIN CANCER RES, V11, P2379, DOI 10.1158/1078-0432.CCR-04-2084
   Hu H, 2008, CLIN CANCER RES, V14, P1150, DOI 10.1158/1078-0432.CCR-07-4037
   Hu YJ, 1997, BIOL TRACE ELEM RES, V56, P331, DOI 10.1007/BF02785304
   Institute. OHR The Newcastle-Ottawa Scale (NOS), OHR NEWC OTT SCAL NO
   Ip C, 2002, CANCER METAST REV, V21, P281, DOI 10.1023/A:1021263027659
   Jablonska E, 2008, EUR J NUTR, V47, P47, DOI 10.1007/s00394-008-0696-9
   Jackson MI, 2008, CURR OPIN CLIN NUTR, V11, P718, DOI 10.1097/MCO.0b013e3283139674
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Kamangar F, 2006, CANCER EPIDEM BIOMAR, V15, P1562, DOI 10.1158/1055-9965.EPI-06-0316
   Karp DD, 2010, J CLIN ONCOLOGY S, V28
   Khan MAK, 2009, ENVIRON TOXICOL CHEM, V28, P1567, DOI 10.1897/08-375.1
   Knizhnikov VA, 1996, NUTR RES, V16, P505, DOI 10.1016/0271-5317(96)00031-0
   Laclaustra M, 2009, ENVIRON HEALTH PERSP, V117, P1409, DOI 10.1289/ehp.0900704
   Larsen EH, 2004, J AOAC INT, V87, P225
   Li DH, 2004, J NUTR, V134, P1536
   Li L, 2005, J BIOCHEM MOL TOXIC, V19, P396, DOI 10.1002/jbt.20105
   Li S, 2007, ANTICANCER RES, V27, P3075
   Li S, 2007, MOL CANCER THER, V6, P1031, DOI 10.1158/1535-7163.MCT-06-0643
   Lippman SM, 2009, JAMA-J AM MED ASSOC, V301, P39, DOI 10.1001/jama.2008.864
   MENKES MS, 1986, NEW ENGL J MED, V315, P1250, DOI 10.1056/NEJM198611133152003
   Micke O, 2000, TRACE ELEM ELECTROLY, V17, P206
   Micke O, 2003, INT J RADIAT ONCOL, V56, P40, DOI 10.1016/S0360-3016(02)04390-0
   Micke O, 2010, FRONT RADIAT THER ON, V42, P198, DOI 10.1159/000262477
   Mucke R, 2004, TRACE ELEM ELECTROLY, V21, P78
   Mucke R, 2006, TRACE ELEM ELECTROLY, V23, P173
   Muecke R, 2010, INT J RAD ONCOL BIOL
   Mueller AS, 2009, FREE RADICAL RES, P1
   OHKAWA K, 1988, BRIT J CANCER, V58, P38, DOI 10.1038/bjc.1988.157
   Prokopczyk B, 1997, CARCINOGENESIS, V18, P1855, DOI 10.1093/carcin/18.9.1855
   Prokopczyk B, 2000, CANCER LETT, V161, P35, DOI 10.1016/S0304-3835(00)00590-5
   Rao M, 1998, J PHARM PHARMACOL, V50, P687, DOI 10.1111/j.2042-7158.1998.tb06906.x
   Ratnasinghe D, 2000, CANCER CAUSE CONTROL, V11, P129, DOI 10.1023/A:1008977320811
   Rayman MP, 2008, BRIT J NUTR, V100, P238, DOI 10.1017/S0007114508922522
   Rayman MP, 2005, P NUTR SOC, V64, P527, DOI 10.1079/PNS2005467
   Reid ME, 2008, NUTR CANCER, V60, P155, DOI 10.1080/01635580701684856
   Reid ME, 2002, CANCER EPIDEM BIOMAR, V11, P1285
   Reid ME, 2004, J TRACE ELEM MED BIO, V18, P69, DOI 10.1016/j.jtemb.2004.03.004
   SATOH M, 1992, CANCER CHEMOTH PHARM, V30, P439, DOI 10.1007/BF00685594
   Schonberg SA, 1997, CARCINOGENESIS, V18, P1897, DOI 10.1093/carcin/18.10.1897
   Schrauzer GN, 2009, CRIT REV BIOTECHNOL, V29, P10, DOI 10.1080/07388550802658048
   Schrauzer GN, 2009, CRIT REV BIOTECHNOL, V29, P2, DOI 10.1080/07388550902728261
   Schroeder CP, 2004, BIOL TRACE ELEM RES, V99, P17, DOI 10.1385/BTER:99:1-3:017
   Silvera SAN, 2007, CANCER CAUSE CONTROL, V18, P7, DOI 10.1007/s10552-006-0057-z
   Smith ML, 2004, ANTICANCER RES, V24, P1401
   Stranges S, 2007, ANN INTERN MED, V147, P217, DOI 10.7326/0003-4819-147-4-200708210-00175
   Swede H, 2003, CANCER EPIDEM BIOMAR, V12, P1248
   Tanaka T, 2000, CANCER RES, V60, P3713
   Thomson CD, 2008, AM J CLIN NUTR, V87, P379
   Vadgama JV, 2000, ANTICANCER RES, V20, P1391
   VERMEULEN NPE, 1993, DRUG METAB DISPOS, V21, P30
   Vinceti Marco, 2009, Reviews on Environmental Health, V24, P231
   Witschi H, 2002, CARCINOGENESIS, V23, P289, DOI 10.1093/carcin/23.2.289
   Witschi H, 2000, EXP LUNG RES, V26, P743, DOI 10.1080/01902140150216792
   Witschi H, 2000, CARCINOGENESIS, V21, P977, DOI 10.1093/carcin/21.5.977
   Xu H, STUDY OXIDATIVE META
   Yamamoto N, 2003, CANCER GENE THER, V10, P445, DOI 10.1038/sj.cgt.7700587
   YU SY, 1990, BIOL TRACE ELEM RES, V24, P105, DOI 10.1007/BF02917199
   Zhang Q.L., 2009, J NANJING MED U, V23, P111
   Zhuo HJ, 2004, CANCER EPIDEM BIOMAR, V13, P771
   Zimmermann T, 2005, BIOL TRACE ELEM RES, V106, P193, DOI 10.1385/BTER:106:3:193
NR 92
TC 36
Z9 37
U1 1
U2 41
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 4
PY 2011
VL 6
IS 11
AR e26259
DI 10.1371/journal.pone.0026259
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 850MH
UT WOS:000297198200006
PM 22073154
OA Green Published, Other Gold
DA 2019-05-24
ER

PT J
AU Fritz, H
   Kennedy, D
   Fergusson, D
   Fernandes, R
   Doucette, S
   Cooley, K
   Seely, A
   Sagar, S
   Wong, R
   Seely, D
AF Fritz, Heidi
   Kennedy, Deborah
   Fergusson, Dean
   Fernandes, Rochelle
   Doucette, Steve
   Cooley, Kieran
   Seely, Andrew
   Sagar, Stephen
   Wong, Raimond
   Seely, Dugald
TI Vitamin A and Retinoid Derivatives for Lung Cancer: A Systematic Review
   and Meta Analysis
SO PLOS ONE
LA English
DT Article
ID BETA-CAROTENE SUPPLEMENTATION; SQUAMOUS-CELL CARCINOMA;
   CHEMOTHERAPY-NAIVE PATIENTS; RANDOMIZED CLINICAL-TRIALS; BASE-LINE
   CHARACTERISTICS; GROWTH-FACTOR RECEPTOR; 2ND PRIMARY TUMORS;
   13-CIS-RETINOIC ACID; EFFICACY TRIAL; CARDIOVASCULAR-DISEASE
AB Background: Despite reported antiproliferative activity of vitamin A and its common use for cancer, there is no comprehensive synthesis of its safety and efficacy in lung cancers. To address this issue we conducted a systematic review of the safety and efficacy of vitamin A for the treatment and prevention of lung cancers.
   Methods and Findings: Two independent reviewers searched six electronic databases from inception to July 2009 for clinical, observational, and preclinical evidence pertaining to the safety and efficacy of vitamin A and related retinoids for lung cancers. 248 studies were included for full review and analysis. Five RCTs assessed treatment of lung cancers, three assessed primary prevention, and three looked at secondary prevention of lung cancers. Five surrogate studies, 26 phase I/II, 32 observational, and 67 preclinical studies were also included. 107 studies were included for interactions between vitamin A and chemo- or radiation-therapy. Although some studies demonstrated benefits, there was insufficient evidence overall to support the use of vitamin A or related retinoids for the treatment or prevention of lung cancers. Retinyl palmitate combined with beta carotene increased risk of lung cancer in smokers in the large CARET trial. Pooling of three studies pertaining to treatment and three studies on secondary prevention revealed no significant effects on response rate, second primary tumor, recurrence, 5-year survival, and mortality. There was a small improvement in event free survival associated with vitamin A compared to controls, RR 1.24 (95% CI 1.13-1.35). The synthetic rexinoid bexarotene increased survival significantly among a subset of patients in two RCTs (p<0.014, <0.087).
   Conclusions: There is a lack of evidence to support the use of naturally occuring retinoids for the treatment and prevention of lung cancers. The rexinoid bexarotene may hold promise for use among a subset of patients, and deserves further study.
C1 [Fritz, Heidi; Kennedy, Deborah; Fernandes, Rochelle; Cooley, Kieran; Seely, Dugald] Canadian Coll Naturopath Med, Dept Res & Epidemiol, Toronto, ON, Canada.
   [Kennedy, Deborah; Cooley, Kieran] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada.
   [Fernandes, Rochelle] Univ Toronto, Lab Med & Pathobiol LMP, Toronto, ON, Canada.
   [Seely, Andrew] Ottawa Hosp Res Inst, Dept Surg, Ottawa, ON, Canada.
   [Sagar, Stephen; Wong, Raimond] McMaster Univ, Dept Med, Juravinski Canc Ctr, Hamilton, ON, Canada.
RP Fritz, H (reprint author), Canadian Coll Naturopath Med, Dept Res & Epidemiol, Toronto, ON, Canada.
EM dseely@ccnm.edu
RI Cooley, Kieran/L-3080-2019
OI Cooley, Kieran/0000-0001-7960-6504; Fergusson, Dean/0000-0002-3389-2485
FU Canadian Institutes of Health Research (CIHR); SickKids Foundation
FX This project was supported by a knowledge synthesis grant from the
   Canadian Institutes of Health Research (CIHR). Deborah Kennedy is
   supported by a career development grant from the SickKids Foundation. No
   additional sources of funding were accessed. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Acin-Perez R, 2010, FASEB J, V24, P627, DOI 10.1096/fj.09-142281
   Albanes D, 1996, J NATL CANCER I, V88, P1560, DOI 10.1093/jnci/88.21.1560
   Albanes D, 1997, AM J CLIN NUTR, V66, P366
   Alberg AJ, 2005, J CLIN ONCOL, V23, P3175, DOI 10.1200/JCO.2005.10.462
   Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012
   *AM CANC SOC, 2010, CANC REF INF WHAT AR
   [Anonymous], 2005, CLIN LUNG CANCER, V7, P17, DOI 10.1016/S1525-7304(11)70385-0
   Ayoub J, 1999, J CLIN ONCOL, V17, P3546, DOI 10.1200/JCO.1999.17.11.3546
   Becker-Witt C, 2003, J ALTERN COMPLEM MED, V9, P113, DOI 10.1089/107555303321222991
   Bertram JS, 2005, BBA-MOL BASIS DIS, V1740, P170, DOI 10.1016/j.bbadis.2005.01.003
   Black HS, 2004, PHOTOCH PHOTOBIO SCI, V3, P753, DOI 10.1039/b316438a
   Blumenschein GR, 2008, J CLIN ONCOL, V26, P1879, DOI 10.1200/JCO.2007.12.2689
   BOLLAG W, 1992, ANN ONCOL, V3, P513, DOI 10.1093/oxfordjournals.annonc.a058252
   Buntzel J, 1998, Auris Nasus Larynx, V25, P413, DOI 10.1016/S0385-8146(98)00040-6
   Clarke Nicole, 2004, Expert Reviews in Molecular Medicine, V6, P1, DOI 10.1017/S1462399404008488
   COLDITZ GA, 1987, ARCH INTERN MED, V147, P157, DOI 10.1001/archinte.147.1.157
   Cook NR, 2000, CANCER CAUSE CONTROL, V11, P617, DOI 10.1023/A:1008995430664
   Danby F William, 2003, Dermatol Online J, V9, P30
   de Klerk NH, 1998, INT J CANCER, V75, P362, DOI 10.1002/(SICI)1097-0215(19980130)75:3<362::AID-IJC6>3.3.CO;2-2
   DiPaolo RS, 1999, J CLIN ONCOL, V17, P2213, DOI 10.1200/JCO.1999.17.7.2213
   Dragnev KH, 2005, J CLIN ONCOL, V23, P8757, DOI 10.1200/JCO.2005.01.9521
   Dragnev KH, 2003, CANCER BIOL THER, V2, pS150
   Dragnev KH, 2007, CLIN CANCER RES, V13, P1794, DOI 10.1158/1078-0432.CCR-06-1836
   *EIS INC, TARGR BEX
   Freemantle SJ, 2006, J NATL CANCER I, V98, P426, DOI 10.1093/jnci/djj116
   Freemantle SJ, 2003, ONCOGENE, V22, P7305, DOI 10.1038/sj.onc.1206936
   FRITSCH PO, 1992, J AM ACAD DERMATOL, V27, pS8, DOI 10.1016/S0190-9622(08)80253-8
   Fu JJ, 2007, CANCER LETT, V248, P153, DOI 10.1016/j.canlet.2006.06.012
   Gackowski D, 2005, INT J CANCER, V114, P153, DOI 10.1002/ijc.20700
   Gagnier JJ, 2006, J CLIN EPIDEMIOL, V59, P1134, DOI 10.1016/j.jclinepi.2005.12.020
   Gallicchio L, 2008, AM J CLIN NUTR, V88, P372
   Goodman GE, 2008, J CLIN ONCOL, V26, P5495, DOI 10.1200/JCO.2008.19.0884
   Goodman GE, 2004, J NATL CANCER I, V96, P1743, DOI 10.1093/jnci/djh320
   GOODMAN GE, 1993, CANCER EPIDEM BIOMAR, V2, P389
   Gregory J, 2009, CURR ONCOL REP, V11, P439, DOI 10.1007/s11912-009-0060-0
   Guarise A, 2008, CANCER IMAGING, V8, P220, DOI 10.1102/1470-7330.2008.0028
   HIGDON J, 2009, CAROTENOIDS ALPHA CA
   HIGDON J, 2009, VITAMIN A
   HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401
   HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Kalemkerian GP, 1998, CANCER-AM CANCER SOC, V83, P1102, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1102::AID-CNCR8>3.0.CO;2-9
   Kamangar F, 2006, CANCER EPIDEM BIOMAR, V15, P1562, DOI 10.1158/1055-9965.EPI-06-0316
   Khuri FR, 2001, J CLIN ONCOL, V19, P2626, DOI 10.1200/JCO.2001.19.10.2626
   Kurie JM, 2000, CLIN CANCER RES, V6, P2973
   Lee IM, 1999, J NATL CANCER I, V91, P2102, DOI 10.1093/jnci/91.24.2102
   LIPPMAN SM, 1993, NEW ENGL J MED, V328, P15, DOI 10.1056/NEJM199301073280103
   Lippman SM, 2001, JNCI-J NATL CANCER I, V93, P605, DOI 10.1093/jnci/93.8.605
   Lonardo F, 1999, CANCER RES, V59, P2470
   Maeno T, 2002, AM J RESP CELL MOL, V26, P246, DOI 10.1165/ajrcmb.26.2.4509
   Matthay KK, 2009, J CLIN ONCOL, V27, P1007, DOI 10.1200/JCO.2007.13.8925
   MCLARTY JW, 1995, AM J CLIN NUTR, V62, P1431
   Meyskens FL, 2005, CANCER EPIDEM BIOMAR, V14, P1366, DOI 10.1158/1055-9965.EPI-04-0666
   MEYSKENS JFL, 1981, P AM ASSOC CANC RES, V22, pC151
   Micke O, 2010, FRONT RADIAT THER ON, V42, P198, DOI 10.1159/000262477
   MICKSCHE M, 1977, ONCOLOGY, V34, P234
   Mitsudomi T, 2010, FEBS J, V277, P301, DOI 10.1111/j.1742-4658.2009.07448.x
   NEELY SM, 1987, ARCH INTERN MED, V147, P529, DOI 10.1001/archinte.147.3.529
   NETTESHEIM P, 1976, CANCER RES, V36, P996
   NETTESHEIM P, 1976, INT J CANCER, V17, P351, DOI 10.1002/ijc.2910170311
   O'Neil C, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006751.pub2
   OLSSON L, 1985, INT J CANCER, V35, P189, DOI 10.1002/ijc.2910350209
   Omenn GS, 2007, EUR J CANCER PREV, V16, P184, DOI 10.1097/01.cej.0000215612.98132.18
   Omenn GS, 1996, J NATL CANCER I, V88, P1550, DOI 10.1093/jnci/88.21.1550
   Omenn GS, 1998, ANNU REV PUBL HEALTH, V19, P73, DOI 10.1146/annurev.publhealth.19.1.73
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Ozpolat B, 2003, J PHARM PHARM SCI, V6, P292
   Parker RS, 1996, FASEB J, V10, P542
   Pasquali D, 2006, CURR PHARM DESIGN, V12, P1923, DOI 10.2174/138161206776873554
   PASTORINO U, 1993, J CLIN ONCOL, V11, P1216, DOI 10.1200/JCO.1993.11.7.1216
   Patrick L, 2000, Altern Med Rev, V5, P530
   PILKINGTON T, 1992, DRUGS, V43, P597, DOI 10.2165/00003495-199243040-00010
   Ramlau R, 2008, J CLIN ONCOL, V26, P1886, DOI 10.1200/JCO.2007.12.2614
   Ray Amitabha, 2005, Indian J Cancer, V42, P15
   Recchia F, 2005, ANTICANCER RES, V25, P3149
   Redlich CA, 1998, CANCER EPIDEM BIOMAR, V7, P211
   Rigas JR, 2005, ONCOLOGIST, V10, P22, DOI 10.1634/theoncologist.10-1-22
   Rizvi N, 2001, Clin Lung Cancer, V2, P210, DOI 10.3816/CLC.2001.n.005
   Roehrs M, 2009, NEPHROL DIAL TRANSPL, V24, P2212, DOI 10.1093/ndt/gfp001
   Ruotsalainen T, 2000, ANTI-CANCER DRUG, V11, P101, DOI 10.1097/00001813-200002000-00006
   RUSCH V, 1995, CANCER RES, V55, P1365
   Siems W, 2002, FASEB J, V16, P1289, DOI 10.1096/fj.01-0765fje
   Smith W, 2005, CRIT REV ONCOL HEMAT, V55, P143, DOI 10.1016/j.critrevonc.2005.02.003
   SMITH WE, 1972, ENVIRON RES, V5, P152, DOI 10.1016/0013-9351(72)90030-8
   Soria JC, 2001, J NATL CANCER I, V93, P1257, DOI 10.1093/jnci/93.16.1257
   Stahl W, 2005, BBA-MOL BASIS DIS, V1740, P101, DOI 10.1016/j.bbadis.2004.12.006
   Tang GW, 2010, AM J CLIN NUTR, V91, p1468S, DOI 10.3945/ajcn.2010.28674G
   Van DE, 2002, COCHRANE DB SYST REV
   van Helden YGJ, 2009, CARCINOGENESIS, V30, P2070, DOI 10.1093/carcin/bgp186
   van Zandwijk N, 2000, JNCI-J NATL CANCER I, V92, P977, DOI 10.1093/jnci/92.12.977
   Virtamo J, 2003, JAMA-J AM MED ASSOC, V290, P476
   Waladkhani AR, 1997, INT J CANCER, V70, P494, DOI 10.1002/(SICI)1097-0215(19970207)70:4<494::AID-IJC24>3.0.CO;2-E
   Wang XD, 1999, J NATL CANCER I, V91, P60, DOI 10.1093/jnci/91.1.60
   Wildi JD, 2008, CHEMOTHERAPY, V54, P125, DOI 10.1159/000119706
   WILKOFF LJ, 1980, P SOC EXP BIOL MED, V163, P233
   Witschi H, 2000, EXP LUNG RES, V26, P743, DOI 10.1080/01902140150216792
   Witschi H, 2000, CARCINOGENESIS, V21, P977, DOI 10.1093/carcin/21.5.977
   Wolf G, 1996, FASEB J, V10, P1102
   1982, EUR J BIOCH, V129, P1
NR 99
TC 32
Z9 32
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 27
PY 2011
VL 6
IS 6
AR e21107
DI 10.1371/journal.pone.0021107
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 783OD
UT WOS:000292092600014
PM 21738614
OA Green Published, Other Gold
DA 2019-05-24
ER

PT J
AU Xiao, L
   Shang, HC
   Wang, JY
   Hu, J
   Xiong, J
AF Xiao Lu
   Shang Hongcai
   Wang Jiaying
   Hu Jing
   Xiong Jun
TI Assessing the Quality of Reports about Randomized Controlled Trials of
   Acupuncture Treatment on Mild Cognitive Impairment
SO PLOS ONE
LA English
DT Article
ID CONSORT STATEMENT
AB Objective: To evaluate the reports' qualities which are about randomized controlled trials (RCTs) of acupuncture treatment on Mild Cognitive Impairment (MIC).
   Methods: Nine databases including the Cochrane Central Register of Controlled Trials (CENTRAL, 2010), PUBMED (1984-5/2010), EMbase (1984-5/2010), MEDLINE (1984-5/2010), CINAL (1984-5/2010), China National Knowledge Infrastructure (CNKI, 1980-5/2010), China Biomedicine Database disc (CBMdisc, 1980-5/2010), VIP (a full text issues database of China, 1989-5/2010) were searched systematically. Hand search for further references was conducted. Language was limited to Chinese and English. We identified 14 RCTs that used acupuncture as an intervention and assessed the quality of these reports against the Consolidated Standards for Reporting of Trials (CONSORT) statement and Standards for Reporting Interventions in Controlled Trials of Acupuncture (STRICTA).
   Results: In regard to the items in the CONSORT statement, 13(92.86%) RCTs described baseline demographic and clinical characteristics in each group. 7 (50.0%) mentioned the method of generating the random sequence, only 2 (14.3%) RCTs had adequate allocation concealment. No RCTs used blinding. RCTs reported the sample size calculation. In regard to the items in STRICTA, 10 (71.43%) mentioned the depths of insertion, 6 (42.86%) reported acupuncture response, 11 (78.57%) mentioned the technique of acupuncture, 12 (85.71%) recorded the time, and only 3 (21.43%) RCTs reported the numbers of needles inserted. No RCTs reported the background of the acupuncture practitioners and professional title of practitioners.
   Conclusion: The reporting quality of RCTs of acupuncture for mild cognitive impairment was moderate to low. The CONSORT statement and STRICTA should be used to standardize the reporting of RCTs of acupuncture in future.
C1 [Xiao Lu; Shang Hongcai; Wang Jiaying] Tianjin Univ Tradit Chinese Med, Tianjin, Peoples R China.
   [Xiao Lu; Shang Hongcai] MOE Virtual Res Ctr Evidence Based Med, Chengdu, Peoples R China.
   [Wang Jiaying] Evidence Based Med Ctr Tianjin, Tianjin, Peoples R China.
   [Hu Jing] Peking Univ, Beijing 100871, Peoples R China.
   [Xiong Jun] Jiang Xi Hosp Tradit Chinese Med, Dept Acupuncture, Nanchang, Jiangxi, Peoples R China.
RP Shang, HC (reprint author), Tianjin Univ Tradit Chinese Med, Tianjin, Peoples R China.
EM shanghongcai@foxmail.com
RI shang, hongcai/H-1257-2014
FU New Century Excellent Talent Project Grant [2009613]
FX New Century Excellent Talent Project Grant (No 2009613). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012
   Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637
   CHEN SJ, 2009, CHINESE J TRADITIONA
   CHEN SJ, 2008, J EMERGENCY TRADITIO
   FENG CQ, 2009, LIN J TRADITIONAL CH, V29
   Gmdman M, 1996, NEUROLOGY, V46, pA403
   HE X, 2008, J PRACTICAL TRADITIO
   HOU XB, 2010, WORLD J INTEGRATED T
   HOU XB, 2009, BRAIN FUNCTIONAL MAG
   LIU J, 2009, SHANGHAI J ACUPUNTUR
   MACPHERSON H, 2001, COMPLEMENT THER MED, P216
   MACPHERSON H, 2001, COMPLEMENT THER MED, V8, P85
   MACPHERSON H, 2001, COMPLEMENT THER MED, V20, P22
   MacPherson Hugh, 2002, Acupunct Med, V20, P22
   Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987
   SU ZW, 2006, LIAONING J TRADITION
   SUN YZ, 2007, CHINESE J TRADITIONA
   SUN YZ, 2009, J CLIN ACUPUNTURE MO
   WANG Y, 2006, J BAOTOU MED COLL, P355
   YU T, 2007, SHAANXI J TRADITIONA
   ZHANG XL, 2006, CHINESE J EVIDENCE B, V6
   ZHOU XP, 2008, GUANGXI J TRADITIONA
   ZHOU XP, 2008, SHANGHAI J ACUPUNTUR
   2009, J ALTERNATIVE COMPLE
NR 24
TC 13
Z9 13
U1 2
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 25
PY 2011
VL 6
IS 2
AR e16922
DI 10.1371/journal.pone.0016922
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 726YS
UT WOS:000287764100015
PM 21364920
OA DOAJ Gold, Green Published
DA 2019-05-24
ER

PT J
AU Kilkenny, C
   Parsons, N
   Kadyszewski, E
   Festing, MFW
   Cuthill, IC
   Fry, D
   Hutton, J
   Altman, DG
AF Kilkenny, Carol
   Parsons, Nick
   Kadyszewski, Ed
   Festing, Michael F. W.
   Cuthill, Innes C.
   Fry, Derek
   Hutton, Jane
   Altman, Douglas G.
TI Survey of the Quality of Experimental Design, Statistical Analysis and
   Reporting of Research Using Animals
SO PLOS ONE
LA English
DT Article
ID CONSORT STATEMENT; GUIDELINES; INSTRUCTIONS; JOURNALS; AUTHORS; HEALTH
AB For scientific, ethical and economic reasons, experiments involving animals should be appropriately designed, correctly analysed and transparently reported. This increases the scientific validity of the results, and maximises the knowledge gained from each experiment. A minimum amount of relevant information must be included in scientific publications to ensure that the methods and results of a study can be reviewed, analysed and repeated. Omitting essential information can raise scientific and ethical concerns. We report the findings of a systematic survey of reporting, experimental design and statistical analysis in published biomedical research using laboratory animals. Medline and EMBASE were searched for studies reporting research on live rats, mice and non-human primates carried out in UK and US publicly funded research establishments. Detailed information was collected from 271 publications, about the objective or hypothesis of the study, the number, sex, age and/or weight of animals used, and experimental and statistical methods. Only 59% of the studies stated the hypothesis or objective of the study and the number and characteristics of the animals used. Appropriate and efficient experimental design is a critical component of high-quality science. Most of the papers surveyed did not use randomisation (87%) or blinding (86%), to reduce bias in animal selection and outcome assessment. Only 70% of the publications that used statistical methods described their methods and presented the results with a measure of error or variability. This survey has identified a number of issues that need to be addressed in order to improve experimental design and reporting in publications describing research using animals. Scientific publication is a powerful and important source of information; the authors of scientific publications therefore have a responsibility to describe their methods and results comprehensively, accurately and transparently, and peer reviewers and journal editors share the responsibility to ensure that published studies fulfil these criteria.
C1 [Kilkenny, Carol] Natl Ctr Replacement Refinement & Reduct Anim Res, London, England.
   [Parsons, Nick] Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England.
   [Kadyszewski, Ed] Pfizer Global Res & Dev, Groton, CT USA.
   [Festing, Michael F. W.] Anim Procedures Comm, London, England.
   [Cuthill, Innes C.] Univ Bristol, Sch Biol Sci, Bristol, Avon, England.
   [Fry, Derek] Home Off, Shrewsbury, Salop, England.
   [Hutton, Jane] Univ Warwick, Dept Stat, Coventry CV4 7AL, W Midlands, England.
   [Altman, Douglas G.] Univ Oxford, Ctr Stat Med, Oxford, England.
RP Kilkenny, C (reprint author), Natl Ctr Replacement Refinement & Reduct Anim Res, London, England.
EM carol.kilkenny@nc3rs.org.uk
RI Altman, Douglas/A-9714-2012
OI Parsons, Nick/0000-0001-9975-888X
FU National Centre for the Replacement, Refinement and Reduction of Animals
   in Research (NC3Rs); National Institutes for Health/Office of Laboratory
   Animal Welfare (NIH/OLAW)
FX This survey was co-funded by the National Centre for the Replacement,
   Refinement and Reduction of Animals in Research (NC3Rs) and the National
   Institutes for Health/Office of Laboratory Animal Welfare
   (NIH/OLAW)(http://grants.nih.gov/grants/olaw/olaw.htm). NIH/OLAW had no
   role in study design, data collection and analysis, or preparation of
   the manuscript. Members of the NC3Rs Experimental Design Working Group
   (EDWG; independent, unpaid experts in experimental design and
   statistics) designed the survey. The NC3Rs paid independent Information
   Specialists to search published databases, and two independent
   statisticians Nick Parsons and Ed Kadyszewski to collect and analyse the
   data. The data were also analysed, and the manuscript prepared and
   submitted, by the NC3Rs (Carol Kilkenny) in consultation with members of
   the EDWG.
CR Alfaro V, 2005, METHOD FIND EXP CLIN, V27, P495, DOI 10.1358/mf.2005.27.7.921309
   Altman DG, 2005, BRIT MED J, V330, P1056, DOI 10.1136/bmj.330.7499.1056
   Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012
   Altman DG, 2008, LANCET, V371, P1149, DOI 10.1016/S0140-6736(08)60505-X
   Bebarta V, 2003, ACAD EMERG MED, V10, P684, DOI 10.1197/aemj.10.6.684
   Bennett LT, 2004, J APPL ECOL, V41, P585, DOI 10.1111/j.0021-8901.2004.00924.x
   BEYNEN AC, 2003, DESIGN ANIMAL EXPT P, P219
   COCHRANE AL, 1972, INT J EPIDEMIOL, V1, P89, DOI 10.1093/ije/1.2.89
   Dell Ralph B, 2002, ILAR J, V43, P207
   Festing M.F., 2002, LAB ANIMAL HDB, V14, P1
   Festing Michael F W, 2002, ILAR J, V43, P244
   FREEMAN JV, 2008, DISPLAY DATA
   Goodacre R, 2007, METABOLOMICS, V3, P231, DOI 10.1007/s11306-007-0081-3
   Hainsworth AH, 2008, J CEREBR BLOOD F MET, V28, P1877, DOI 10.1038/jcbfm.2008.91
   Jafari Peyman, 2006, BMC Med Inform Decis Mak, V6, P27, DOI 10.1186/1472-6947-6-27
   Johnson Paula D, 2002, ILAR J, V43, P202
   Macleod MR, 2008, STROKE, V39, P2824, DOI 10.1161/STROKEAHA.108.515957
   Macleod MR, 2009, STROKE, V40, P50
   MCCANCE I, 1995, AUST VET J, V72, P322, DOI 10.1111/j.1751-0813.1995.tb07534.x
   Morris CE, 2002, MICROBIOL MOL BIOL R, V66, P592, DOI 10.1128/MMBR.66.4.592-616.2002
   Nakagawa S, 2007, BIOL REV, V82, P591, DOI 10.1111/j.1469-185X.2007.00027.x
   Obrink KJ, 2000, LAB ANIM, V34, P121, DOI 10.1258/002367700780457608
   Peters JL, 2006, J ENVIRON SCI HEAL B, V41, P1245, DOI 10.1080/03601230600857130
   Russell W. M. S., 1959, PRINCIPLES HUMANE EX
   Shaw Robert, 2002, ILAR J, V43, P223
   Smidt N, 2005, RADIOLOGY, V235, P347, DOI 10.1148/radiol.2352040507
   Smith JA, 1997, LAB ANIM, V31, P312, DOI 10.1258/002367797780596176
   Stone SP, 2007, J ANTIMICROB CHEMOTH, V59, P833, DOI 10.1093/jac/dkm055
   Tooth L, 2005, AM J EPIDEMIOL, V161, P280, DOI 10.1093/aje/kwi042
   von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X
   *WORK COMM BIOL CH, 1985, LAB ANIM, V19, P106
NR 31
TC 335
Z9 348
U1 4
U2 66
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 30
PY 2009
VL 4
IS 11
AR e7824
DI 10.1371/journal.pone.0007824
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 533MQ
UT WOS:000272828400001
PM 19956596
OA Other Gold, Green Published
HC Y
HP N
DA 2019-05-24
ER

PT J
AU Cohan, D
   Gomez, E
   Greenberg, M
   Washington, S
   Charlebois, ED
AF Cohan, Deborah
   Gomez, Elvira
   Greenberg, Mara
   Washington, Sierra
   Charlebois, Edwin D.
TI Patient Perspectives with Abbreviated versus Standard Pre-Test HIV
   Counseling in the Prenatal Setting: A Randomized-Controlled,
   Non-Inferiority Trial
SO PLOS ONE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; DECISION AID; POSTMENOPAUSAL WOMEN;
   PREGNANT-WOMEN; THERAPY
AB Background: In the US, an unacceptably high percentage of pregnant women do not undergo prenatal HIV testing. Previous studies have found increased uptake of prenatal HIV testing with abbreviated pre-test counseling, however little is known about patient decision making, testing satisfaction and knowledge in this setting.
   Methodology/Findings: A randomized-controlled, non-inferiority trial was conducted from October 2006 through February 2008 at San Francisco General Hospital (SFGH), the public teaching hospital of the City and County of San Francisco. A total of 278 English-and Spanish-speaking pregnant women were randomized to receive either abbreviated or standard nurse-performed HIV test counseling at the initial prenatal visit. Patient decision making experience was compared between abbreviated versus standard HIV counseling strategies among a sample of low-income, urban, ethnically diverse prenatal patients. The primary outcome was the decisional conflict score (DCS) using O'Connor low-literacy scale and secondary outcomes included satisfaction with test decision, basic HIV knowledge and HIV testing uptake. We conducted an intention-to-treat analysis of 278 women -134 (48.2%) in the abbreviated arm (AA) and 144 (51.8%) in the standard arm (SA). There was no significant difference in the proportion of women with low decisional conflict (71.6% in AA vs. 76.4% in SA, p = .37), and the observed mean difference between the groups of 3.88 (95% CI: -0.65, 8.41) did not exceed the non-inferiority margin. HIV testing uptake was very high (97.8%) and did not differ significantly between the 2 groups (99.3% in AA vs. 96.5% in SA, p = .12). Likewise, there was no difference in satisfaction with testing decision (97.8% in AA vs. 99.3% in SA, p = .36). However, women in AA had significantly lower mean HIV knowledge scores (78.4%) compared to women in SA (83.7%, p<0.01).
   Conclusions/Significance: This study suggests that streamlining the pre-test counseling process, while associated with slightly lower knowledge, does not compromise patient decision making or satisfaction regarding HIV testing.
   Trial Registration: Clinical Trials. gov NCT00503308
RP Cohan, D (reprint author), Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA.
EM cohand@obgyn.ucsf.edu
FU NIDA NIH HHS [K23DA016174, K23 DA016174]
CR Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012
   Branson Bernard M., 2006, Morbidity and Mortality Weekly Report, V55, P1
   BRANSON BM, 2006, MMWR RECOMM REP, V55, pCE11
   Carusi D, 1998, OBSTET GYNECOL, V91, P540, DOI 10.1016/S0029-7844(97)00714-X
   Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P1013
   Chou R, 2005, ANN INTERN MED, V143, P38, DOI 10.7326/0003-4819-143-1-200507050-00009
   Cohan D, 2008, JAIDS-J ACQ IMM DEF, V49, P571, DOI 10.1097/QAI.0b013e31818d5e11
   Cranney A, 2002, PATIENT EDUC COUNS, V47, P245, DOI 10.1016/S0738-3991(01)00218-X
   DIXON WJ, 1983, INTRO STAT ANAL
   Gattellari M, 2004, J MED SCREEN, V11, P165, DOI 10.1258/0969141042467386
   Kuppermann M, 2006, OBSTET GYNECOL, V107, P1087, DOI 10.1097/01.AOG.0000214953.90248.db
   Kuppermann M, 2009, OBSTET GYNECOL, V113, P53, DOI 10.1097/AOG.0b013e31818e7ec4
   LALONDE L, 2006, INT J PHARM PRACT, V14, P51, DOI DOI 10.1211/ijpp.14.1.0007
   Laupacis A, 2006, PATIENT EDUC COUNS, V61, P458, DOI 10.1016/j.pec.2005.05.014
   Man-Son-Hing M, 1999, JAMA-J AM MED ASSOC, V282, P737, DOI 10.1001/jama.282.8.737
   Murray E, 2001, BMJ-BRIT MED J, V323, P490, DOI 10.1136/bmj.323.7311.490
   *NAT HIV AIDS CLIN, 2008, COMP STAT HIV TEST L
   O'Connor AM, 1998, MED DECIS MAKING, V18, P295, DOI 10.1177/0272989X9801800307
   OBRIEN R, 1993, APPL ANAL VARIANCE B
   OCONNOR AM, 1995, MED DECIS MAKING, V15, P25, DOI 10.1177/0272989X9501500105
   *OTT HLTH RES I OT, US MAN DEC CONFL SCA
   Phillips KA, 1997, J ACQ IMMUN DEF SYND, V14, P174, DOI 10.1097/00042560-199702010-00012
   Piaggio G, 2006, JAMA-J AM MED ASSOC, V295, P1152, DOI 10.1001/jama.295.10.1152
   Rahangdale L, 2008, J WOMENS HEALTH, V17, P465, DOI 10.1089/jwh.2007.0545
   Siminoff Laura A., 2000, Health Expect, V3, P26, DOI 10.1046/j.1369-6513.2000.00074.x
   Simpson W M, 1999, Health Technol Assess, V3, P1
   Simpson WM, 1998, BRIT MED J, V316, P262, DOI 10.1136/bmj.316.7127.262
   Stacey D, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001431.pub2, 10.1002/14651858.CD001431.pub3]
   Stringer EM, 2001, OBSTET GYNECOL, V98, P1104, DOI 10.1016/S0029-7844(01)01631-3
   *US DEP HHS, 2002, RED OBST BARR OFF HI
   2002, MMWR MORB MORTAL WKL, V51, P93
NR 31
TC 9
Z9 9
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 15
PY 2009
VL 4
IS 4
AR e5166
DI 10.1371/journal.pone.0005166
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 437TS
UT WOS:000265510400002
PM 19367335
OA Other Gold, Green Published
DA 2019-05-24
ER

PT J
AU Siegfried, N
   Clarke, M
   Volmink, J
   Van der Merwe, L
AF Siegfried, Nandi
   Clarke, Michael
   Volmink, Jimmy
   Van der Merwe, Lize
TI African HIV/AIDS Trials Are More Likely to Report Adequate Allocation
   Concealment and Random Generation than North American Trials
SO PLOS ONE
LA English
DT Article
AB Background: Adherence to good methodological quality is necessary to minimise bias in randomised conrolled trials (RCTs). Specific trial characteristics are associated with better trial quality, but no studies to date are specific to HIV/AIDS or African trials. We postulated that location may negatively impact on trial quality in regions where resources are scarce.
   Methods: 1) To compare the methodological quality of all HIV/AIDS RCTs conducted in Africa with a random sample of similar trials conducted in North America; 2) To assess whether location is predictive of trial quality. We searched MEDLINE, EMBASE, CENTRAL and LILACS. Eligible trials were 1) randomized, 2) evaluations of preventive or treatment interventions for HIV/AIDS, 3) reported before 2004, and 4) conducted wholly or partly (if multi-centred) in Africa or North America. We assessed adequacy of random generation, allocation concealment and masking of assessors. Using univariate and multivariate logistic regression analyses we evaluated the association between location (Africa versus North America) and these domains.
   Findings: The African search yielded 12,815 records, from which 80 trials were identified. The North American search yielded 13,158 records from which 785 trials were identified and a random sample of 114 selected for analysis. African trials were three times more likely than North American trials to report adequate allocation concealment (OR = 3.24; 95% CI: 1.59 to 6.59; p < 0.01) and twice as likely to report adequate generation of the sequence (OR = 2.36; 95% CI: 1.20 to 4.67; p = 0.01), after adjusting for other confounding factors. Additional significant factors positively associated with quality were an a priori sample size power calculation, restricted randomization and inclusion of a flow diagram detailing attrition. We did not detect an association between location and outcome assessor masking.
   Conclusions: The higher quality of reporting of methodology in African trials is noteworthy. Most African trials are externally funded, and it is possible that stricter agency requirements when leading trials in other countries and greater experience and training of principal investigators of an international stature, may account for this difference.
C1 [Siegfried, Nandi; Clarke, Michael] Univ Oxford, Clin Trial Serv Unit, Oxford, England.
   [Siegfried, Nandi; Clarke, Michael] United Kingdom Cochrane Ctr, Oxford, England.
   [Volmink, Jimmy] Univ Stellenbosch, Fac Hlth Sci, ZA-7600 Stellenbosch, South Africa.
   [Van der Merwe, Lize] MRC, Biostat Unit, Cape Town, South Africa.
   [Van der Merwe, Lize] Univ Western Cape, Dept Stat, ZA-7535 Bellville, South Africa.
RP Siegfried, N (reprint author), MRC, S African Cochrane Ctr, Cape Town, South Africa.
EM nandi.siegfried@mrc.ac.za
RI van der Merwe, Lize/C-9445-2013
OI van der Merwe, Lize/0000-0001-9705-8126
FU Nuffield Dominions Trust
FX Nandi Siegfried was supported by the Nuffield Dominions Trust. The
   funder was not involved in the design and conduct of the study, or in
   the collection, management, analysis, and interpretation of the data, or
   in the preparation, review, or approval of the manuscript.
CR Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012
   Altman DG, 1991, PRACTICAL STAT MED R
   Balasubramanian SP, 2006, ANN SURG, V244, P663, DOI 10.1097/01.sla.0000217640.11224.05
   Ballantyne A, 2005, BIOETHICS, V19, P476, DOI 10.1111/j.1467-8519.2005.00459.x
   Boutron I, 2003, JAMA-J AM MED ASSOC, V290, P1062, DOI 10.1001/jama.290.8.1062
   Chan AW, 2005, BRIT MED J, V330, P753, DOI 10.1136/bmj.38356.424606.8F
   Cohen J, 2000, SCIENCE, V288, P2155, DOI 10.1126/science.288.5474.2155
   *COMM REV HIVNET 0, 2005, REV HIVNET 012 PER H
   Crumley Ellen T, 2005, BMC Med Res Methodol, V5, P24, DOI 10.1186/1471-2288-5-24
   Edejer TTT, 1999, BRIT MED J, V319, P438, DOI 10.1136/bmj.319.7207.438
   Edwards P, 2002, STAT MED, V21, P1635, DOI 10.1002/sim.1190
   Egger M, 2001, JAMA-J AM MED ASSOC, V285, P1996, DOI 10.1001/jama.285.15.1996
   *ENCY BRIT, 2007, ENCY BRIT ONL
   Gluud LL, 2005, AM J GASTROENTEROL, V100, P2431, DOI 10.1111/j.1572-0241.2005.00327.x
   Gonzalez-Block Miguel A, 2004, Health Res Policy Syst, V2, P6, DOI 10.1186/1478-4505-2-6
   GROOPMAN JE, 1984, ANN INTERN MED, V100, P671, DOI 10.7326/0003-4819-100-5-671
   Ha TC, 2006, ANN ACAD MED SINGAP, V35, P911
   Horton R, 2000, LANCET, V355, P2231, DOI 10.1016/S0140-6736(00)02414-4
   Hosmer D. W., 2000, APPL LOGISTIC REGRES
   JUNI P, 2001, SYSTEMATIC REV HLTH, P87
   Kjaergard LL, 1999, HEPATOLOGY, V30, P1134, DOI 10.1002/hep.510300510
   Kjaergard LL, 2002, AM J GASTROENTEROL, V97, P2708
   Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212
   MOHER D, 2001, LANCET, V357, P1194
   Royston P, 2006, STAT MED, V25, P127, DOI 10.1002/sim.2331
   Ruiz-Canela M, 2001, J MED ETHICS, V27, P172, DOI 10.1136/jme.27.3.172
   Schulz KF, 2002, JAMA-J AM MED ASSOC, V288, P2406, DOI 10.1001/jama.288.19.2406
   SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408
   SCHULZ KF, 1995, CAN MED ASSOC J, V153, P783
   SEGLEN O., 1997, BMJ, V314
   Siegfried N, 2005, BRIT MED J, V331, P742, DOI 10.1136/bmj.331.7519.742
   Sim I, 2006, LANCET, V367, P1631, DOI 10.1016/S0140-6736(06)68708-4
   Soares HP, 2004, BRIT MED J, V328, P22, DOI 10.1136/bmj.328.7430.22
   *US NAT LIB MED, 2007, ABR IND MED AIM J TI
   Yousefi-Nooraie Reza, 2006, BMC Med Res Methodol, V6, P37, DOI 10.1186/1471-2288-6-37
   2000, LANCET, V356, P1043
NR 36
TC 6
Z9 6
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 22
PY 2008
VL 3
IS 10
AR e3491
DI 10.1371/journal.pone.0003491
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 432IG
UT WOS:000265126100022
PM 18941523
OA DOAJ Gold, Green Published
DA 2019-05-24
ER

PT J
AU Grande, T
   Bernasconi, A
   Erhart, A
   Gamboa, D
   Casapia, M
   Delgado, C
   Torres, K
   Fanello, C
   Llanos-Cuentas, A
   D'Alessandro, U
AF Grande, Tanilu
   Bernasconi, Andrea
   Erhart, Annette
   Gamboa, Dioni
   Casapia, Martin
   Delgado, Christopher
   Torres, Kathy
   Fanello, Caterina
   Llanos-Cuentas, Alejandro
   D'Alessandro, Umberto
TI A Randomised Controlled Trial to Assess the Efficacy of
   Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated
   Falciparum Malaria in Peru
SO PLOS ONE
LA English
DT Article
AB Background. Multi-drug resistant falciparum malaria is an important health problem in the Peruvian Amazon region. We carried out a randomised open label clinical trial comparing mefloquine-artesunate, the current first line treatment in this region, with dihydroartemisinin-piperaquine. Methods and Findings. Between July 2003 and July 2005, 522 patients with P. falciparum uncomplicated malaria were recruited, randomized (260 with mefloquine-artesunate and 262 with dihydroartemisinin-piperaquine), treated and followed up for 63 days. PCR-adjusted adequate clinical and parasitological response, estimated by Kaplan Meier survival and Per Protocol analysis, was extremely high for both drugs (99.6% for mefloquine-artesunate and 98.4% and for dihydroartemisinin-piperaquine) (RR: 0.99, 95% CI [0.9721.01], Fisher Exact p = 0.21). All recrudescences were late parasitological failures. Overall, gametocytes were cleared faster in the mefloquine-artesunate group (28 vs 35 days) and new gametocytes tended to appear more frequently in patients treated with dihydroartemisinin-piperaquine (day 7: 8 (3.6%) vs 2 (0.9%), RR: 3.84, 95% CI [0.82-17.87]). Adverse events such as anxiety and insomnia were significantly more frequent in the mefloquine-artesunate group, both in adults and children. Conclusion. Dihydroartemisinin-piperaquine is as effective as mefloquine-artesunate in treating uncomplicated P. falciparum malaria but it is better tolerated and more affordable than mefloquine-artesunate (US$1.0 versus US$18.65 on the local market). Therefore, it should be considered as a potential candidate for the first line treatment of P. falciparum malaria in Peru. Trial Registration. ClinicalTrials.gov NCT00373607 [http://www.clinicaltrials.gov/ct/show/NCT00373607]
C1 [Bernasconi, Andrea; Erhart, Annette; D'Alessandro, Umberto] Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium.
   [Grande, Tanilu; Gamboa, Dioni; Delgado, Christopher; Torres, Kathy; Llanos-Cuentas, Alejandro] Univ Peruana Cayetano Heredia, ITM AvH, Lima, Peru.
   [Casapia, Martin] Minist Salud Peru, Direcc Reg Salud Loreto, Lima, Peru.
   [Fanello, Caterina] London Sch Hyg & Trop Med, London WC1, England.
RP Erhart, A (reprint author), Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium.
EM aerhart@itg.be
RI Delgado Ratto, Christopher/D-3838-2013; D'Alessandro,
   Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009; Fanello,
   Caterina/0000-0003-1932-9562; Gamboa, Dionicia/0000-0002-1420-7729
FU Directorate-General for Development and Cooperation (DGDC) of the
   Belgian Government [95501]
FX Funding: Financial support was provided by the Directorate-General for
   Development and Cooperation (DGDC) of the Belgian Government (framework
   agreement 02, project 95501).
CR Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012
   Ashley EA, 2004, J INFECT DIS, V190, P1773, DOI 10.1086/425015
   Cattamanchi A, 2003, AM J TROP MED HYG, V68, P133, DOI 10.4269/ajtmh.2003.68.133
   CHAUCA H, 1993, REV PERUANA EPIDEMIO, V6, P34
   Davis TME, 2005, DRUGS, V65, P75, DOI 10.2165/00003495-200565010-00004
   Denis MB, 2002, CLIN INFECT DIS, V35, P1469, DOI 10.1086/344647
   Guarda JA, 1999, EMERG INFECT DIS, V5, P209
   Hien TT, 2004, LANCET, V363, P18, DOI 10.1016/S0140-6736(03)15163-X
   Janssens B, 2007, TROP MED INT HEALTH, V12, P251, DOI 10.1111/j.1365-3165.2006.01786.x
   KAREMA C, 2006, T R SOC TROP MED HYG, V438, P1
   KARUNAJEEWA H, 2003, BR J CLIN PHARM, V57, P193
   Marquino W, 2003, AM J TROP MED HYG, V68, P608, DOI 10.4269/ajtmh.2003.68.608
   Mayxay M, 2006, TROP MED INT HEALTH, V11, P1157, DOI 10.1111/j.1365-3156.2006.01671.x
   *MIN HLTH PER, 2004, RES INT SURV ADV EV
   Mugittu K, 2006, TROP MED INT HEALTH, V11, P1350, DOI 10.1111/j.1365-3156.2006.01688.x
   NAVITSKY RC, 1997, AM J TROP MED HYG  S, V57, P229
   *OF GEN EP PER, 2006, WEEKL EP B
   Olliaro P L, 2004, J Postgrad Med, V50, P40
   Roshanravan B, 2003, AM J TROP MED HYG, V69, P45, DOI 10.4269/ajtmh.2003.69.45
   RUEBUSH T, 2003, REV PERU MED EXP SAL, V20, P162
   Smithuis F, 2006, LANCET, V367, P2075, DOI 10.1016/S0140-6736(06)68931-9
   Snounou G, 1999, T ROY SOC TROP MED H, V93, P369, DOI 10.1016/S0035-9203(99)90120-7
   WHO, 2003, ASS MON ANT DRUG EFF
   *WHO, 1980, MAN BAS TECHN HLTH L, P379
NR 24
TC 26
Z9 27
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 31
PY 2007
VL 2
IS 10
AR e1101
DI 10.1371/journal.pone.0001101
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V10IW
UT WOS:000207458700018
PM 17971864
OA Green Published, Other Gold
DA 2019-05-24
ER

PT J
AU Cobo, E
   Selva-O'Callagham, A
   Ribera, JM
   Cardellach, F
   Dominguez, R
   Vilardell, M
AF Cobo, Erik
   Selva-O'Callagham, Albert
   Ribera, Josep-Maria
   Cardellach, Francesc
   Dominguez, Ruth
   Vilardell, Miquel
TI Statistical Reviewers Improve Reporting in Biomedical Articles: A
   Randomized Trial
SO PLOS ONE
LA English
DT Article
AB Background. Although peer review is widely considered to be the most credible way of selecting manuscripts and improving the quality of accepted papers in scientific journals, there is little evidence to support its use. Our aim was to estimate the effects on manuscript quality of either adding a statistical peer reviewer or suggesting the use of checklists such as CONSORT or STARD to clinical reviewers or both. Methodology and Principal Findings. Interventions were defined as 1) the addition of a statistical reviewer to the clinical peer review process, and 2) suggesting reporting guidelines to reviewers; with "no statistical expert'' and "no checklist'' as controls. The two interventions were crossed in a 262 balanced factorial design including original research articles consecutively selected, between May 2004 and March 2005, by the Medicina Clinica (Barc) editorial committee. We randomized manuscripts to minimize differences in terms of baseline quality and type of study (intervention, longitudinal, cross-sectional, others). Sample-size calculations indicated that 100 papers provide an 80% power to test a 55% standardized difference. We specified the main outcome as the increment in quality of papers as measured on the Goodman Scale. Two blinded evaluators rated the quality of manuscripts at initial submission and final post peer review version. Of the 327 manuscripts submitted to the journal, 131 were accepted for further review, and 129 were randomized. Of those, 14 that were lost to follow-up showed no differences in initial quality to the followed-up papers. Hence, 115 were included in the main analysis, with 16 rejected for publication after peer review. 21 (18.3%) of the 115 included papers were interventions, 46 (40.0%) were longitudinal designs, 28 (24.3%) cross-sectional and 20 (17.4%) others. The 16 (13.9%) rejected papers had a significantly lower initial score on the overall Goodman scale than accepted papers (difference 15.0, 95% CI: 4.6-24.4). The effect of suggesting a guideline to the reviewers had no effect on change in overall quality as measured by the Goodman scale (0.9, 95% CI: -0.3-+2.1). The estimated effect of adding a statistical reviewer was 5.5 (95% CI: 4.3-6.7), showing a significant improvement in quality. Conclusions and Significance. This prospective randomized study shows the positive effect of adding a statistical reviewer to the field-expert peers in improving manuscript quality. We did not find a statistically significant positive effect by suggesting reviewers use reporting guidelines.
C1 [Cobo, Erik; Dominguez, Ruth] Technol Univ Catalonia, Dept Stat & Operat Res, Barcelona, Spain.
   [Selva-O'Callagham, Albert; Vilardell, Miquel] Hosp Gen Valle Hebron, Dept Internal Med, Barcelona, Spain.
   [Ribera, Josep-Maria] Univ Hosp, Dept Hematol, Barcelona, Spain.
   [Cardellach, Francesc] Hosp Clin Barcelona, Dept Med, Barcelona, Spain.
   [Cardellach, Francesc] Univ Barcelona, Barcelona, Spain.
   [Cobo, Erik; Selva-O'Callagham, Albert; Ribera, Josep-Maria; Cardellach, Francesc; Vilardell, Miquel] Med Clin, Barcelona, Spain.
RP Cobo, E (reprint author), Technol Univ Catalonia, Dept Stat & Operat Res, Barcelona, Spain.
EM erik.cobo@upc.edu
RI Cobo, Erik/H-6230-2011
OI Cobo, Erik/0000-0002-3534-5602
FU Carlos III Institute of Health [PI041945]
FX This study was funded by grant PI041945 from the Carlos III Institute of
   Health (to E. C. and A. S.).
CR ALCMAN D, 1999, PEER REV HLTH SCI, P157
   Altman DG, 2002, JAMA-J AM MED ASSOC, V287, P2765, DOI 10.1001/jama.287.21.2765
   Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012
   Arnau C, 2003, MED CLIN-BARCELONA, V121, P690, DOI 10.1157/13054597
   Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637
   Bosch F, 2003, MED CLIN-BARCELONA, V121, P228, DOI 10.1157/13050000
   Bossuyt PM, 2003, CLIN CHEM, V49, P7, DOI 10.1373/49.1.7
   CALLAHAM ML, 2001, JAMA-J AM MED ASSOC, V287, P2781
   Campanelli M, 1998, MULTIBODY SYST DYN, V2, P277, DOI 10.1023/A:1009758701296
   Campbell MK, 2004, BMJ-BRIT MED J, V328, P702, DOI 10.1136/bmj.328.7441.702
   Des Jarlais DC, 2004, AM J PUBLIC HEALTH, V94, P361, DOI 10.2105/AJPH.94.3.361
   Enserink M, 2001, SCIENCE, V293, P2187
   GARDNER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1355, DOI 10.1001/jama.263.10.1355
   Godlee F, 1998, JAMA-J AM MED ASSOC, V280, P237, DOI 10.1001/jama.280.3.237
   GOODMAN SN, 1994, ANN INTERN MED, V121, P11, DOI 10.7326/0003-4819-121-1-199407010-00003
   GORE SM, 1992, LANCET, V340, P100, DOI 10.1016/0140-6736(92)90409-V
   Hanks G, 2005, PALLIATIVE MED, V19, P359, DOI 10.1191/0269216305pm1039ed
   Jefferson T, 2002, JAMA-J AM MED ASSOC, V287, P2784, DOI 10.1001/jama.287.21.2784
   Lee KP, 2002, JAMA-J AM MED ASSOC, V287, P2805, DOI 10.1001/jama.287.21.2805
   LOCK S, 1994, ANN INTERN MED, V121, P60, DOI 10.7326/0003-4819-121-1-199407010-00012
   Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987
   Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5
   MORARIPOLL M, 1999, MED CLIN-BARCELONA, V113, P138
   NYLENNA M, 1994, JAMA-J AM MED ASSOC, V272, P149, DOI 10.1001/jama.272.2.149
   Pierie JPEN, 1996, LANCET, V348, P1480, DOI 10.1016/S0140-6736(96)05016-7
   Porta M, 2006, INT J EPIDEMIOL, V35, P1130, DOI 10.1093/ije/dyl196
   RENNIE D, 1992, CONTROL CLIN TRIALS, V13, P443, DOI 10.1016/0197-2456(92)90201-A
   Ridker PM, 2006, JAMA-J AM MED ASSOC, V295, P2270, DOI 10.1001/jama.295.19.2270
   ROSS J, 2006, JAMA-J AM MED ASSOC, V295, P167
   Scarpa T, 2006, SCIENCE, V311, P41, DOI 10.1126/science.1122796
   Schriger DL, 2006, ANN EMERG MED, V48, P750, DOI 10.1016/j.annemergmed.2006.06.017
   Schroter S, 2004, BRIT MED J, V328, P658, DOI 10.1136/bmj.328.7441.658
   Smith JA, 2002, J UROLOGY, V168, P2123, DOI 10.1097/01.ju.0000034385.02340.99
   *STROBE GROUP, STROBE STAT
   van Rooyen S, 1998, JAMA-J AM MED ASSOC, V280, P234, DOI 10.1001/jama.280.3.234
   van Rooyen S, 1999, BRIT MED J, V318, P23
   2002, JAMA, V287, P2749
   2000, NAT STRUCT BIOL, V7, P1075
   2001, NATURE, V413, P93
NR 39
TC 36
Z9 37
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 28
PY 2007
VL 2
IS 3
AR e332
DI 10.1371/journal.pone.0000332
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V10DR
UT WOS:000207445200015
PM 17389922
OA Other Gold, Green Published
DA 2019-05-24
ER

EF